Contents	**Page No.**

****

Corporate Information

BOARD OF DIRECTORS

Mr. Sanjay Manocha (DIN: 00076997)	Managing Director
Mr. Kartik Palta (DIN: 01543913)	Whole Time Director
Mr. Yogesh Sachdeva (DIN: 00077095)	Whole Time Director
Mrs. Archna Manocha (DIN: 02020796)	Director and Chief Financial Officer
Dr. Neelam Sachdeva (DIN: 11612103)	Independent Director
CA Vishal Gupta (DIN: 11612079)	Independent Director
Mr. Rajiv Jasuja (DIN: 11622255)	Independent Director
Dr. Prashant Jain (DIN: 11669639)	Non-Executive Director

SENIOR MANAGEMENT

CS Vidushi	Company Secretary and Compliance officer

STATUTORY AUDITORS

M/S SURENDER KUMAR SINGHAL & CO., *Chartered Accountants*
303-304B, Apra Plaza 'B', Plot No. 28, Road No. 44,
Community Centre, Pitam Pura, New Delhi-110034

BANKERS

Bank of India,
Punjab National Bank
State Bank of India

REGISTERED OFFICE

N-1, Lower Ground Floor, Satyawati Colony, Ashok Vihar, Phase-III, Delhi-110052.

CORPORATE OFFICE

14, Central Market, Lower Ground Floor, Ashok Vihar, Delhi-110052, India

WORKS

Plot No. 230-231, 24 & 31, Sector-38, HSIIDC, Phase 1, Rai Sonipat, Haryana-131029, India

CORPORATE PHILOSOPHY

- **Become leading research based ethical pharmaceutical formulation company.**
- **Provide product of highest quality, while ensuring profitable growth and enhancement of wealth of the shareholders and all stakeholders.**
- **Make research, innovation and new technologies Product our guiding mantra.**
- **Direct efforts to ensure people live healthy and fuller lives and discharge our social responsibility.**

SCEPTRE MEDICAL (INDIA) LIMITED

(Formerly known as Sceptre Medical (India) Private Limited)

CIN: U33112DL2010PLC204626

Registered Office: Lower Ground Floor, N-1, Satyawati Colony, Ashok Vihar, Phase- III, North West Delhi, Delhi, India, 110052

Tel: 011 4155 8987; Website: www.sceptremedical.com

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the Sixteenth (16th) Annual General Meeting of the Members of Sceptre Medical (India) Limited (Formerly known as Sceptre Medical (India) Private Limited) will be held on **Sunday, 27th day of September 2026**, **at 12.00 P.M.** at the registered office of the Company at **N-1, Lower Ground Floor, Satyawati Colony, Ashok Vihar, Phase-III, North west Delhi, Delhi-110052**, to transact the following businesses:

ORDINARY BUSINESS

1. To receive, consider and adopt:

a) the audited Standalone Financial Statements of the Company for the financial year ended 31st March, 2026 together with the Reports of the Board of Directors and Auditors thereon.

b) the audited Consolidated Financial Statements of the Company for the financial year ended 31st March, 2026 together with the Reports of the Auditors thereon.

2. To appoint a director in place of Mrs. Archna Manocha (DIN :02020796), Director, who retires by rotation and being eligible to offer herself for re-appointment.

3. To re-appoint Surender Kumar Singhal & Co., Chartered Accountants as statutory auditors of the Company and to fix their remuneration.

To consider and if thought fit, to pass the following resolution, as an ordinary resolution:

RESOLVED THAT pursuant to Sections 139, 142 and all other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, (including any statutory modification(s) or re-enactment thereof) and pursuant to the recommendations of the Audit Committee and the Board of Directors of the Company, Surender Kumar Singhal & Co., Chartered Accountants, having firm registration No. 009156N be and are hereby re-appointed as the Statutory Auditors of the Company for a term of five consecutive years, who shall hold office from the conclusion of this 16th Annual General Meeting till the conclusion of the 21st Annual General Meeting to be held in the financial year 2031-32 on such remuneration as may be decided by the Board of Directors in consultation with the Statutory Auditors of the Company."

By Order of the Board
For **Sceptre Medical (India) Limited**
(Formerly known as Sceptre Medical (India) Private Limited)

Sd/-
Vidushi
Company Secretary & Compliance officer

Place: New Delhi
Date: 05.09.2026

NOTES:

1. A member who is entitled to attend and vote is entitled to appoint a proxy instead of attending meeting through himself/herself and such proxy need not be a member of the company. The proxy in order to be effective must be received at the company's registered office not less than 48 hours before the time of holding of the meeting. The proxy form is attached herewith.

2. Members are requested to bring their copy of the Annual Report to the Meeting, as copies of the Annual Report will not be distributed at the venue of the Meeting. Members/Proxies are requested to bring the duly filled and signed Attendance Slip for attending the Meeting.

3. Members desiring any information or clarification related with the accounts or otherwise are requested to write to the Company at its Registered Office at least 7 days before the date of the Annual General Meeting so as to enable the management to keep the information ready.

SCEPTRE MEDICAL (INDIA) LIMITED

(Formerly known as Sceptre Medical (India) Private Limited)

CIN: U33112DL2010PLC204626

Registered Office: Lower Ground Floor, N-1, Satyawati Colony, Ashok Vihar, Phase- III, North West Delhi, Delhi, India, 110052

Tel: 011 4155 8987; Website: www.sceptremedical.com

BOARD'S REPORT

To
The Members of,
Sceptre Medical (India) Limited
(Formerly known as Sceptre Medical (India) Private Limited)
Lower Ground Floor, N-1, Satyawati Colony,
Ashok Vihar, Phase III, Delhi, 110052, India

The Directors are pleased to present you the 16th Annual Report of **SCEPTRE MEDICAL (INDIA) LIMITED** along with the audited financial statement (both standalone and consolidated) for the financial year ending 31st March, 2026.

1. FINANCIAL SUMMARY OR HIGHLISHTS /OPERATIONAL AND FINANCIAL PERFORMANCE OF THE COMPANY

During the year under review, The Company earned a profit of Rs. 1090.41 Lakhs before tax for the year ended March 31, 2026 on a standalone basis. A summary of the financial performance of the Company on standalone and consolidated basis for the financial year ended March 31, 2026 is given below:

(Amount in Lakh)

Particulars	Standalone		Consolidated	
	2025-26 Current Year	2024-25 Previous Year	2025-26 Current Year	2024-25 Previous Year
Revenue from Operations	4,778.99	2,869.45	6794.51	2869.45
Add.: Other Income	49.94	6.09	50.70	6.09
Total Revenue	**4,828.93**	**2,875.54**	**6845.21**	**2875.54**
Less: Total Expenses (except Depreciation and Amortization Exp.)	3,666.28	2,324.65	5282.05	2324.65
Profit (before Depreciation and Tax)	**1,162.65**	**550.89**	**1563.16**	**550.89**
Less: Total Depreciation and Amortization Expenses	72.24	70.07	107.52	70.07
Profit (before exceptional and extraordinary items and Tax)	**1,090.41**	**480.82**	**1455.64**	**480.82**
Share of Profit of Associate accounted for using Equity Method	-	-	**38.71**	**4.94**
Profit (before Tax)	**1,090.41**	**480.82**	**1494.35**	**485.76**
Tax Expenses:				
Less: Current Tax	257.77	125.00	351.99	125.00
Add: Deferred Tax	(7.75)	(35.28)	(10.96)	(35.28)

Profit/Loss for the Year	**840.39**	**391.10**	**1153.32**	**396.04**
Share of Profit attributable to • **Parent Company** • **Minority Interest**	 **-** **-**	 **-** **-**	 **1129.90** **23.42**	 **396.04** **-**
Earning per equity shares (Basic & Diluted)	66.45	33.37	91.19	33.79

The Company is engaged in the manufacturing, trading, supply and distribution of infection control, hygiene and medical products. Its product portfolio includes antiseptics, disinfectants, medical and personal hygiene wet wipes, dialysis-related consumables and other medical devices and hospital consumables, catering to hospitals, clinics, dialysis center, healthcare institutions and retail customers. The Company's operations are supported by its manufacturing, quality control and distribution capabilities, with a continued focus on product quality, safety and regulatory compliance.

During the financial year under review, the Company achieved a significant improvement in its financial performance and earned a net profit of **₹840.39 lakhs**, as compared to a net profit of **₹391.10 lakhs** in the previous financial year 2024-25. The substantial growth in profitability reflects improved operational performance, continued business growth and the Company's focus on operational efficiency.

The Company continued to strengthen its presence across the infection control, hygiene, nephrology and critical care segments. Through its diversified product portfolio and manufacturing and distribution capabilities, the Company remains focused on meeting the evolving requirements of the healthcare sector, strengthening relationships with its customers and business partners, and pursuing sustainable growth and long-term value creation.

2. <u>TRANSFER TO ANY RESERVES</u>

The Board of Directors does not propose to transfer any profits to reserves.

3. <u>DIVIDEND</u>

During the financial year under review, company earned standalone net profit of Rs. 840.39 lakhs and consolidated net profit of Rs. 1153.32 lakhs. For the better growth of the Company, Board of Directors decided to retain all the profit earned during the financial year. Therefore, the directors of the Company did not recommend any dividend for the financial year under review.

4. <u>TRANSFER OF UNCLAIMED DIVIDEND AND UNCLAIMED SHARES:</u>

Company has not declared dividend in any of the previous years. During the financial year under review, there were no unclaimed/unpaid or outstanding amounts, required to be transferred, to the Investor Education and Protection Fund.

5. <u>STATE OF THE COMPANY'S AFFAIR</u>

The principal business activity of the Company is to manufacture, supply and distribution of Infection control, hygiene and medical products. Its portfolio includes antiseptics, disinfectants, wet wipes and dialysis related consumables, catering to hospitals, clinics, institutional healthcare settings and retails setting. With a strong focus on quality safety, and innovation, the Company delivers reliable products across infection control, personal hygiene, nephrology, and critical care segments, supported by robust manufacturing and distribution capabilities.

There was no change in the nature of business of the Company during the year under review.

6. CONSOLIDATED FINANCIAL STATEMENTS

The Consolidated Financial Statements of the company for the financial year 2025-26 are prepared in compliance with applicable provisions of the Companies Act, 2013 and Accounting Standard issued by Institute of Chartered Accountants of India.

7. ANNUAL RETURN

The Annual return of the Company as on 31st March, 2026, in the Form MGT-7 in accordance with Section 92(3) and 134(3)(9) of the Act as amended from time to time and the Companies (Management and Administration) Rules, 2014 is available on the website of the Company at https://www.sceptremedical.com/

8. MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY THAT OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THIS FINANCIAL STATEMENT RELATES AND THE DATE OF THE REPORT

After the end of the financial year under review, Bonus Shares was allotted to the shareholders of the Company on 08.04.2026 out of the amount standing credited to the Securities Premium Account and Statement of Profit and Loss Account.

9. DETAILS OF SUBSIDIARY, JOINT VENTURE OR ASSOCIATE COMPANIES

The Company has total 2 (Two) subsidiary companies namely (i) Sceptre Medical Devices Private Limited (ii) M. S. Medicals Private Limited. The company has no Associate Company or Joint Venture Companies within the meaning of section 2(6) of the Companies Act, 2013.

The Company entered into Holding and Subsidiary Relationship with Sceptre Medical Devices Private Limited through the control of composition of Board of Directors.

Pursuant to provisions of section 129(3) of the Companies Act, 2013, a statement Containing salient features of the financial statements of the Company's subsidiaries in **Form AOC-1** is attached herewith as **Annexure-A.**

Further, the consolidated financial statements along with relevant documents and separate audited accounts in respect of subsidiaries are available at the registered office of the company.

10. DETAILS OF DIRECTORS AND KEY MANEGERIAL PERSONNEL

APPOINTMENT AND RESIGNATION OF DIRECTORS

During the financial year under review, Dr. Neelam Sachdeva, CA Vishal Gupta, Mr. Rajiv Jasuja were appointed as Additional Non-Executive Independent Directors of the Company with effect from March 23, 2026, and was subsequently regularized as an Independent Director of the Company at the Extra-ordinary General Meeting held on March 30, 2026.

Further, Dr. Prashant Jain was appointed as a Non-Executive Director of the Company with effect from 30.03.2026 in the Extra-ordinary General Meeting held on March 30, 2026.

Further, Mr. Yogesh Sachdva and Mr. Kartik Palta were appointed as a Whole Time Director of the Company w.e.f 23rd day of March, 2026.

As on March 31, 2026, the Board of Directors of the Company comprised Eight (8) Directors, whose names and designations are as under:

1. Mr. Sanjay Manocha, Managing Director
2. Mrs. Archna Manocha, Director
3. Mr. Yogesh Sachdeva, Whole Time Director
4. Mr. Kartik Palta, Whole Time Director
5. Dr. Neelam Sachdeva, Non-Executive Independent Director
6. CA Vishal Gupta, Non-Executive Independent Director
7. Mr. Rajiv Jasuja, Non-executive Independent Director
8. Dr. Prashant Jain, Non-Executive Director

The composition of the Board of Directors as on March 31, 2026, is in compliance with the provisions of Section 149 of the Companies Act, 2013 and the Rules made thereunder. The Company has duly appointed Independent Directors on the Board, and they have submitted declarations confirming that they meet the criteria of independence as prescribed under Section 149(6) of the Companies Act, 2013.

RETIRE BY ROTATION AND RE-APPOINTMENT

As per the provisions of Section 152(6) of Companies Act, 2013, Mrs. Archna Manocha (DIN: 02020796), director of the Company, liable to retire by rotation at ensuing annual general meeting and, being eligible, offers herself for re-appointment.

CHIEF FINANCIAL OFFICER

During the financial year under review, Mrs. Archna Mnocha was appointed as Chief Financial officer of the Company w.e.f 23rd day of March, 2026.

COMPANY SECRETARY AND COMPLIANCE OFFICER

During the financial year under review, Ms. Vidushi (Membership No.: A71077), Associate member of the Institute of Company Secretaries of India, was appointed as Company Secretary of the Company w.e.f 01st day of March, 2026.

11. DECLARATION OF INDEPENDENT DIRECTORS

The Independent Directors have submitted their declaration of Independence, stating that:

a) They continue to fulfil the criteria of independence provided in Section 149 (6) of the Act along with Rules framed thereunder and
b) There has been no change in the circumstances affecting their status as Independent Directors of the Company.

The Board opined and confirm, in terms of Rule 8 of the Companies (Accounts) Rules, 2014 that the Independent Directors are persons of high repute, integrity and possess the relevant expertise and experience in their respective fields.

12. COMPLIANCE WITH APPLICABLE SECRETARIAL STANDARDS

The Company has duly followed the applicable Secretarial standards, relating to Meeting of the Board of Directors (SS-1) and General Meeting (SS-2), issued by the Institute of Company Secretaries of India (ICSI).

13. BOARD MEETINGS

During the year under review, the Board met 26 (Twenty-Six) times. The intervening gap between the two consecutive Board Meetings was within the prescribed period of 120 days as specified under the provisions of Section 173 of the Act.

Following is the attendance of each of the Directors at the Board Meetings held during the period under review:

S. No.	Date of Meeting	Total No. of Directors as on date of meeting	Attendance	
			No. of Directors attended	% of attendance
1	17.04.2025	5	5	100
2	18.06.2025	5	5	100
3	23.06.2025	5	5	100
4	02.07.2025	4	4	100
5	14.07.2025	4	4	100
6	01.08.2025	4	4	100
7	02.08.2025	4	4	100
8	18.08.2025	4	4	100
9	02.09.2025	4	4	100
10	23.09.2025	4	4	100
11	03.10.2025	4	4	100
12	07.10.2025	4	4	100

13	14.10.2025	4	4	100
14	17.10.2025	4	4	100
15	29.10.2025	4	4	100
16	06.11.2025	4	4	100
17	17.11.2025	4	4	100
18	01.12.2025	4	4	100
19	02.12.2025	4	4	100
20	24.12.2025	4	4	100
21	12.02.2026	4	4	100
22	17.02.2026	4	4	100
23	09.03.2026	4	4	100
24	16.03.2026	4	4	100
25	20.03.2026	4	4	100
26	23.03.2026	4	4	100

14. COMMITTEES ON THE BOARD

AUDIT COMMITTEE

The composition of the Audit Committee and terms of reference are in compliance with the provisions of Section 177 of the Act. All members of the Committee are financially literate and have accounting or related financial management expertise.

The Terms of reference broadly includes the following:

i) the recommendation for appointment, remuneration and terms of appointment of auditors of the company;
ii) review and monitor the auditor's independence and performance, and effectiveness of audit process;
iii) examination of the financial statement and the auditors' report thereon;
iv) approval or any subsequent modification of transactions of the company with related parties;
v) scrutiny of inter-corporate loans and investments;
vi) valuation of undertakings or assets of the company, wherever it is necessary;
vii) evaluation of internal financial controls and risk management systems;
viii) monitoring the end use of funds raised through public offers and related matters.

During the Financial year under review, No Audit Committee was constituted as it was not applicable to constitute as per the Provisions of the Companies Act, 2013.

After the financial year under review, as on April 20, 2026, the Audit Committee of the Company was constituted as per the provisions of Section 177 of the Companies Act, 2013 and the Rules made thereunder. The Audit Committee now comprises the following members:

S. No	Name	Designation & Category	Position in Committee
1	CA Vishal Gupta	Non-Executive Independent Director	Chairman
2	Dr. Neelam Sachdeva	Non-Executive Independent Director	Member

3	Mrs. Archna Manocha	Director	Member

NOMINATION AND REMUNERATION COMMITTEE

During the financial year under review, the provisions relating to the constitution of the Nomination and Remuneration Committee under Section 178 of the Companies Act, 2013 ("the Act"), were not applicable to the Company. Accordingly, no Nomination and Remuneration Committee was constituted during the financial year.

Subsequent to the close of the financial year, the Company constituted the Nomination and Remuneration Committee on April 20, 2026, in accordance with the applicable provisions of Section 178 of the Act and the Rules made thereunder. The composition and terms of reference of the Committee are in compliance with the applicable provisions of the Act.

The Nomination and Remuneration Committee presently comprises the following members:

S. No	Name	Designation & Category	Position in Committee
1	CA Vishal Gupta	Non-Executive Independent Director	Chairman
2	Dr. Prashant Jain	Non-Executive Director	Member
3	Mr. Rajiv Jasuja	Non-Executive Independent Director	Member

CORPORATE SOCIAL RESPONSIBILITY COMMITTEE

During the financial year under review, the provisions relating to Corporate Social Responsibility under Section 135 of the Companies Act, 2013 ("the Act"), were not applicable to the Company. Accordingly, no Corporate Social Responsibility Committee was constituted during the financial year.

Subsequent to the close of the financial year, the provisions of Section 135 of the Act became applicable to the Company. Accordingly, the Corporate Social Responsibility Committee was constituted on April 20, 2026, in accordance with the provisions of Section 135 of the Act and the Rules made thereunder.

The Corporate Social Responsibility Committee presently comprises the following members:

S. No	Name	Designation & Category	Position in Committee
1	Dr. Neelam Sachdeva	Non-Executive Independent Director	Chairman
2	Mr. Sanjay Manocha	Managing Director	Member
3	Mr. Kartik Palta	Whole Time Director	Member

STAKEHOLDER RELATIONSHIP COMMITTEE

During the financial year under review, the provisions relating to the constitution of the Stakeholders Relationship Committee under the Companies Act, 2013 ("the Act"), were not applicable to the Company. Accordingly, no Stakeholders Relationship Committee was constituted during the financial year.

Subsequent to the close of the financial year, the Stakeholders Relationship Committee of the Company was constituted on April 20, 2026, in accordance with the applicable provisions of the Act and the Rules made thereunder.

The Stakeholders Relationship Committee presently comprises the following members:

S. No	**Name**	**Designation & Category**	**Position in Committee**
1	CA Vishal Gupta	Non-Executive Independent Director	Chairman
2	Mr. Sanjay Manocha	Managing Director	Member
3	Mr. Yogesh Sachdeva	Whole Time Director	Member

15. DIRECTORS RESPONSIBILITY STATEMENT

As required under Section 134 of the Act (including any statutory modification(s) and/or re-enactment(s) thereof for the time being in force), the Directors of the Company state that:

a. in the preparation of the annual accounts for the financial year ended March 31, 2026, the applicable accounting standards had been followed along with the proper explanation relating to material departures;
b. the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as on March 31, 2026, and of its profit and loss for the financial year ended on that date;
c. the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
d. the Director had prepared the annual accounts for the financial year 2025-26 on a ‘going concern’ basis; and

the Directors had devised proper systems to ensure compliance with the provisions of all the applicable laws and that such systems are adequate and operating effectively.

16. MAINTENANCE OF COST RECORDS

The provisions relating to maintenance of cost records as specified by the Central Government under Section 148 of the Companies Act, 2013, read with the applicable rules made thereunder, are not applicable to the Company during the period under review. Accordingly, the Company has not maintained cost records during the period under review.

17. CAPITAL STRUCTURE

During the financial year under review, the Authorized Share Capital of the Company was increased to **₹25,00,00,000/- (Rupees Twenty-Five Crores only)**, divided into **2,50,00,000 (Two Crore Fifty Lakh)**

Equity Shares of ₹10/- (Rupees Ten only) each, subject to the necessary approvals and in accordance with the applicable provisions of the Companies Act, 2013.

Subsequent to the close of the financial year, the Paid-up Share Capital of the Company was increased pursuant to the allotment of Bonus Equity Shares to the eligible shareholders of the Company. Consequently, the Paid-up Share Capital of the Company increased to **₹17,51,18,060/- (Rupees Seventeen Crore Fifty-One Lakh Eighteen Thousand Sixty only)**.

The aforesaid increase in the share capital reflects the Company's continued growth and strengthens its capital base, thereby supporting its future business plans and long-term growth objectives.

Shares with differential voting rights and sweat equity shares:

The Company has not issued shares with differential voting rights and sweat equity shares during the year under review.

18. PARTICULARS OF LOANS, GUARANTEES, SECURITY OR INVESTMENTS MADE UNDER SECTION 186 OF THE COMPANIES ACT, 2013

During the financial year under review, the Company provided loans to its wholly owned subsidiary company in accordance with the applicable provisions of Section 186 of the Companies Act, 2013 and the Rules made thereunder. The Company duly complied with all applicable provisions, approvals and requirements prescribed under the Companies Act, 2013 in respect of such transactions.

The requisite particulars of the loans, guarantees, securities and investments covered under Section 186 of the Companies Act, 2013 have been disclosed in the notes forming part of the Financial Statements.

19. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES MADE PURSUANT TO SECTION 188 OF THE COMPANIES ACT, 2013

Transaction with related parties were conducted in a transparent manner in the best interest of the Company and Stakeholders. All the transactions entered into with the related parties during the year under review were in the ordinary course of business and on an arm's length basis.

Pursuant to the provisions of Section 134(3)(h) of the Act, the particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Act and prescribed in **Form AOC-2** of Companies (Accounts) Rules, 2014, is annexed to this Report as **"Annexure-B".**

However complete regular details of the transactions with related parties have been taken note in financial statements of the Company according to the requirements of the AS-18. **(Refer Note No. 32 of Financial Statements)**

20. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

CONSERVATION OF ENERGY, TECHNOLOGIES ABSORPTION

The information relating to conservation of Energy, Technology absorption, Foreign Exchange earnings and outgo as required to be disclosed under Section 134(3) (m) of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014 is enclosed as **Annexure-C** and forms part of this report.

FOREIGN EXCHCHANGE EARNINGS AND OUTGO

During the financial year under review, the details of the foreign exchange earnings and outgo are as follows:

Particulars	**For the year ended 31.03.2026**	**For the year ended 31.03.2025**
1. CIF Value of Imports	38.82	-
2. Expenditure in Foreign Currency	-	-
a. Outward Remittance	48.21	
b. Travel Expenditure	-	4.22
3. Consumption of imported Raw Material components and spare parts	12.51	-
4. Earning in foreign currency	9.13	-

(Refer Note No. 33 of Financial Statements)

21. STATEMENT INDICATING DEVELOPMENT AND IMPLEMENTATION OF RISK MANAGEMENT POLICY

The Company is exposed to inherent uncertainties owing to the sectors in which it operates. A key factor in determining company's capacity to create sustainable value is the risks that the company is willing to take (at strategic and operational levels) and its ability to manage them effectively. Many risks exist in a company's operating environment and they emerge on a regular basis. The Company's Risk Management Process focuses on ensuring that these risks are identified on a timely basis and addressed. The Company has devised and implemented a mechanism for risk management and has developed a Risk Management Policy to identify, evaluate business risks and opportunities. This policy seeks to create transparency, minimize adverse impact on the business objectives and enhance the Company's competitive advantage. The business risk management policy defines the risk management approach across the enterprise at various levels including documentation and reporting. The Company has identified various risks and also has mitigation plans for each risk identified.

22. DETAILS OF SIGNIFICANT MATERIAL ORDERS PASSED BY THE REGULATORS / COURTS / TRIBUNAL IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATION IN FUTURE

During the year under review, the Company has not received any significant orders/ material orders passed by any of Regulators/ Courts/ Tribunals impacting the going concern status of the Company and its operations in future.

23. VIGIL MECHANISM/WHISTLE BLOWER POLICY

The provisions relating to the establishment of a Vigil Mechanism under Section 177(9) of the Companies Act, 2013 are not applicable to the Company. Accordingly, the Company is not required to formulate a Vigil Mechanism/Whistle Blower Policy.

24. DEPOSITS

During the year under review, the Company has not accepted any deposits within the meaning of Sections 73 and 74 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014.

25. UNSECURED LOAN FROM DIRECTORS

During the year under review, the Company has accepted unsecured loans from its directors to meet its business and working capital requirements. The loans have been accepted in accordance with the applicable provisions of the Companies Act, 2013 and the rules made thereunder.

26. COMPANY'S POLICY RELATING TO DIRECTORS' APPOINTMENT, PAYMENT OF REMUNERATION TO DIRECTORS AND DISCHARGE OF THEIR DUTIES

The Nomination and Remuneration Committee works with the Board to determine the appropriate characteristics, skills and experience for the Board as a whole and its individual members with the objective of having a Board with diverse backgrounds and experience in business, government, education and public service. Characteristics expected of all directors include independence, integrity, high personal and professional ethics, sound business judgment, ability to participate constructively in deliberations and willingness to exercise authority in a collective manner.

The remuneration paid to the Directors, Key Managerial Personnel and Senior Management is as per the Companies Act, 2013 and relevant rules made thereunder.

27. FAMILIARISATION PROGRAM FOR INDEPENDENT DIRECTORS

The Independent Directors are regularly informed during meetings of the Board and Committees on the business strategy, business activities, manufacturing operations, updates on the drone industry, and regulatory updates. The Directors when they are appointed are given a detailed orientation on the Company, industry, strategy, policies and Code of Conduct, regulatory matters, business, financial matters, human resource matters, and Corporate Social Responsibility initiatives of the Company.

28. BOARD EVALUATION

The annual evaluation of performance of the Board of Directors, its committees, Chairman and individual Directors for the year under review was conducted in accordance with the provisions of the Companies Act, 2013.

The performance of the board was evaluated after seeking inputs from all the directors on the basis of the criteria such as the board composition and structure, effectiveness of board processes, information and functioning etc.

The performance of the committees was evaluated by the board after seeking inputs from the committee members on the basis of the criteria such as the composition of committees, effectiveness of committee meetings, etc.

The board and the nomination and remuneration committee reviewed the performance of the individual directors on the basis of the criteria such as the contribution of the individual director to the board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings etc.

The performance of the board as a whole and performance of the Managing Director was evaluated, taking into account the views of executive directors and non-executive directors. The same was duly discussed at the board meeting.

29. REGISTRAR AND SHARE TRANSFER AGENT

During the year under review, Beetal Financial & Computers Services Private Limited was appointed as Registrar and Transfer Agent of the Company.

30. ALLOTMENT OF ISIN

During the period under review, The Company has obtained the International Securities Identification Number (ISIN) **INE22GG01017** for its Equity Shares. The ISIN facilitates the dematerialisation and electronic holding and transfer of the Company's securities in accordance with the applicable provisions of the Companies Act, 2013 and the rules and regulations made thereunder.

31. BUY-BACK OF SECRURITIES

The Company has not bought back any of its securities during the financial year under review.

32. CREDIT RATING:

No credit rating was obtained by the Company during the financial year under review.

33. DETAILS OF EMPLOYEE STOCK OPTIONS

The Company does not have any Employee Stock Option Scheme/ Plan.

34. STATUTORY AUDITORS

During the financial year under review, M/s. Surender Kumar Singhal & Co., Chartered Accountants (Firm Registration No. 009156N), having its office at 303-304B, Apra Plaza ‘B’, Plot No. 28, Road No. 44, Community Centre, Pitampura, New Delhi – 110034, were appointed as the Statutory Auditors of the Company to fill the casual vacancy arising out of the resignation of M/s. RGMG & Co., Chartered Accountants, with effect from December 22, 2025. The appointment was duly approved by the Members of the Company at an Extra-Ordinary General Meeting, in accordance with the applicable provisions of the Companies Act, 2013 and the Rules made thereunder.

M/s. Surender Kumar Singhal & Co., Chartered Accountants, shall hold office until the conclusion of the ensuing Annual General Meeting of the Company, in accordance with the applicable provisions of the Companies Act, 2013.

The Statutory Auditors have confirmed that they satisfy the criteria prescribed under Sections 139 and 141 of the Companies Act, 2013 and are eligible for appointment as the Statutory Auditors of the Company. They have further confirmed that they are not disqualified from continuing in office as the Statutory Auditors of the Company.

The Audit Report issued by the Statutory Auditors for the financial year under review does not contain any qualification, reservation, adverse remark or disclaimer. The observations and comments, if any, contained in the Auditor's Report, read together with the relevant notes forming part of the Financial Statements, are self-explanatory and, therefore, do not call for any further comments or explanation from the Board.

35. EXPLANATIONS / COMMENTS ON QUALIFICATION, RESERVATION OR ADVERSE REMARK OR DISCLAIMER MADE BY THE AUDITOR IN THE AUDIT REPORT

Auditor‘s Remarks:

There is no qualifications, reservations, adverse remark or disclaimer in Auditors Report

36. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has zero tolerance towards sexual harassment at the workplace. The company has adopted a policy in line with the provisions of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made thereunder. All employees (permanent contractual, temporary, trainees) are covered under the said policy. An Internal Complaints Committee has also been set up to redress complaints received on sexual harassment.

During the financial year under review, the Company has not received any complaints of sexual harassment from any of the women employees of the Company.

37. COMPLIANCE WITH THE MATERNITY BENEFIT ACT, 1961

The Company has complied with the provisions of the Maternity Benefit Act, 1961, including all applicable amendments and rules framed thereunder. The Company is committed to ensuring a safe, inclusive, and supportive workplace for women employees. The Company also ensures that no discrimination is made in recruitment or service conditions on the grounds of maternity. Necessary internal systems and HR policies are in place to uphold the spirit and letter of the legislation.

38. GENDER-WISE COMPOSITION OF EMPLOYEES

In alignment with the principles of diversity, equity, and inclusion (DEI), the Company discloses below the gender composition of its workforce as on the March 31, 2026.

Male Employees: 56
Female Employees: 19
Transgender Employees: 0

This disclosure reinforces the Company's efforts to promote an inclusive workplace culture and equal opportunity for all individuals, regardless of gender.

39. DOWNSTREAM INVESTMENT

During the year, Company does not have any Foreign Direct Investment. However, the Company is having investments in its subsidiary companies incorporated in India.

40. DETAILS OF REVISION OF FINANCIAL STATEMENT OR THE REPORT

The company has not revised the financial statement or board report during the year under review.

41. INTERNAL FINANCIAL CONTROLS RELATED TO FINANCIAL STATEMENTS

The Company has an adequate system of Internal Financial Control commensurate with its size and scale of operations, procedures and policies, ensuring efficient and orderly conduct of its business, including adherence to the Company's policy, safeguarding of its assets, prevention and detection of frauds and errors, accuracy and completeness of accounting records and timely preparation of reliable financial information.

Based on the assessment carried out by the Management and the evaluation of the results of the assessment, the Board is of the opinion that the Company has adequate Internal Financial Control System that is operating effectively during the year under review.

There were no instances of fraud which necessitates reporting of material mis-statement to the Company's operations.

42. REPORTING OF FRAUDS

During the year under review, there have been no frauds reported by the Statutory Auditors of the Company under sub-section (12) of Section 143 of the Act.

43. DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 DURING THE YEAR ALONG WITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR

During the year under review and till date of this Report, the Company has neither made any application against anyone nor any proceedings were pending against the Company under the Insolvency and Bankruptcy Code, 2016.

44. DETAILS OF DIFFERENCE BETWEEN THE AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF

During the financial year under review, the Company had outstanding borrowings from banks and /or financial institutions in the ordinary course of its business. The Company has been regular in servicing its debts obligations, including repayment of principal and interest/EMIs, in accordance with the agreed terms.

The Company has not entered into any One Settlement ("OTS") arrangement with any bank or financial institution during the financial year under review.
Accordingly, the disclosure relating to the difference between the amount of valuation undertaken at the time of One Settlement and the valuation undertaken while availing loans from banks or financial institutions is not applicable to the Company

45. CORPORATE GOVERNANCE

However, the company is not bind as per law to prepare corporate governance report but we ensure that we evolve and follow the corporate governance guidelines and best practices sincerely to not just boost long-term shareholder value, but to also respect minority rights. We consider it our inherent responsibility to disclose timely and accurate information regarding our financials and performance, as well as the leadership and governance of the Company. Company aspires to be the global sugar industry benchmark for value creation and corporate citizenship. In addition to that company expects to realize its vision by taking such actions as may be necessary to achieve its goals of value creation, safety of environment and people etc.

46. ACKNOWLEDGEMENT

The Board of Directors places on record its gratitude to the government and regulatory authorities, correspondent banks, for their support. The Board acknowledges the support of the shareholders and also places on record its sincere thanks to its valued client for its continued patronage. The Board also appreciates to all employees of the Company for their sincere work and commitment.

On behalf of Board of Directors,
For **SCEPTRE MEDICAL (INDIA) LIMITED**
(Formerly known as Sceptre Medical (India) Private Limited)

Sd/-	**Sd/-**	**Sd/-**	**Sd/-**
Sanjay Manocha	**Yogesh Sachdeva**	**Kartik Palta**	**Archna Manocha**
(Managing Director)	**(Whole Time Director)**	**(Whole Time Director)**	**(Director)**
DIN 00076997	**DIN: 00077095**	**DIN: 01543913**	**DIN: 02020796**

Date: 05.09.2026
Place: New Delhi

Annexure-A

Form AOC- 1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2O14)

Statement containing salient features of the financial statement of Subsidiaries or associate Companies or Joint Ventures

PART- A: SUBSIDIARIES

(1)

1. Name of the subsidiary	**M. S. Medicals Private Limited**
2. The date since when subsidiary was acquired	**01.04.2025**
3. Reporting period for the subsidiary concerned, if different from the holding company's reporting period.	**N. A**
4. Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries.	**N. A**
5. Share capital	**95.40 Lakhs**
6. Reserves and surplus	**551.35 Lakhs**
7. Total assets	**2,379.50**
8. Total Liabilities	**1,732.75 Lakhs**
9. Investments	**NIL**
10. Turnover	**3,916.08 Lakhs**
11. Profit before taxation	**313.07 Lakhs**
12. Provision for taxation	**66.59 Lakhs**
13. Profit after taxation	**235.19**
14. Proposed Dividend	**NIL**
15. Extent of shareholding (in percentage)	**100**

(2)

1. Name of the subsidiary	**Sceptre Medical Devices Private Limited**
2. The date since when subsidiary was acquired	**30.03.2026 (Earlier it was an Associate Company)**
3. Reporting period for the subsidiary concerned, if different from the holding company's reporting period.	**N. A**
4. Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries.	**N. A**
5. Share capital	**93.00 Lakhs**
6. Reserves and surplus	**247.82 Lakhs**
7. Total assets	**1,316.21 Lakhs**
8. Total Liabilities	**975.39 Lakhs**
9. Investments	**NIL**
10. Turnover	**1,620.04 Lakhs**
11. Profit before taxation	**17.72 Lakhs**
12. Provision for taxation	**28.93**

13. Profit after taxation	**135.81**
14. Proposed Dividend	**NIL**
15. Extent of shareholding (in percentage)	**40% (Subsidiary by way of control of Composition of Board of Directors)**

1. There are no other subsidiaries which are yet to commence operations.
2. There are no subsidiaries which have liquidated during the year.

Part-B: Associates and Joint Ventures Statement

(Pursuant to Section 129 (3) of the Companies Act, 2O13 related to Associate Companies and Joint Ventures)

1. Company does not have any other Associate/Joint Ventures Company at the end of the financial year 2025-26. Therefore, there is no need to attach here “Part-B” (Information regarding Associate/ Joint Ventures Companies) of this form.
2. There are no other associates and join ventures which are yet to commence operations.
3. There are no associates and Joint ventures which have liquidated during the year.

On behalf of Board of Directors,
For **SCEPTRE MEDICAL (INDIA) LIMITED**
(Formerly known as Sceptre Medical (India) Private Limited)

Sd/-
Sanjay Manocha
(Managing Director)
DIN 00076997

Sd/-
Yogesh Sachdeva
(Whole Time Director)
DIN: 00077095

Sd/-
Kartik Palta
(Whole Time Director)
DIN: 01543913

Sd/-
Archna Manocha
(Director)
DIN: 02020796

Date: 05.09.2026
Place: New Delhi

Annexure-B

FORM NO. AOC-2

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

1. **Details of contracts or arrangements or transactions not at arm's length basis:**

(a) Name(s) of the related party and nature of relationship- **N.A**
(b) Nature of contracts/arrangements/transactions-**N.A**
(c) Duration of the contracts/arrangements/transactions-**N.A**
(d) Salient terms of the contracts or arrangements or transactions including the value, if any-**N.A**
(e) Justification for entering into such contracts or arrangements or transactions-**N.A**
(f) Date(s) of approval by the Board-**N.A**
(g) Amount paid as advances, if any-**N.A**
(h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188-**N.A**

2. **Details of material contracts or arrangement or transactions at arm's length basis:** The Company has entered into 17 (Seventeen) contract/arrangements with related parties during the period under review:

(I)

(a) Name(s) of the related party and/ nature of relationship: Sanjay Manocha **/ Key Management Personnel**
(b) Nature of contracts/arrangements/transactions: **Loan Received**
(c) Duration of the contracts/arrangements/transactions: **ongoing basis**
(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **119.50 Lakhs**
(e) Date(s) of approval by the Board, if any: 17.04.2025
(f) Amount paid as advances, if any: **N.A.**

(II)

(a) Name(s) of the related party and/ nature of relationship: Kartik Palta **/ Key Management Personnel**
(b) Nature of contracts/arrangements/transactions: **Loan Received**
(c) Duration of the contracts/arrangements/transactions: **ongoing basis**

(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **44.84 Lakhs**

(e) Date(s) of approval by the Board, if any: 17.04.2025

(f) Amount paid as advances, if any: **N.A.**

(III)

(a) Name(s) of the related party and/ nature of relationship: Yogesh Sachdeva **/ Key Management Personnel**

(b) Nature of contracts/arrangements/transactions: **Loan Received**

(c) Duration of the contracts/arrangements/transactions: **ongoing basis**

(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **241.15 Lakhs**

(e) Date(s) of approval by the Board, if any: 17.04.2025

(f) Amount paid as advances, if any: **N.A.**

(IV)

(a) Name(s) of the related party and/ nature of relationship: Kartik Palta **/ Key Management Personnel**

(b) Nature of contracts/arrangements/transactions: **Repayment of Loan**

(c) Duration of the contracts/arrangements/transactions: Ongoing

(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **79.84 Lakhs**

(e) Date(s) of approval by the Board, if any: 17.04.2025

(f) Amount paid as advances, if any: **N.A.**

(V)

(a) Name(s) of the related party and/ nature of relationship: Sanjay Manocha **/ Key Management Personnel**

(b) Nature of contracts/arrangements/transactions: **Repayment of Loan**

(c) Duration of the contracts/arrangements/transactions: **Ongoing**

(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **166.47 Lakhs**

(e) Date(s) of approval by the Board, if any: 17.04.2025

(f) Amount paid as advances, if any: **N.A.**

(VI)

(a) Name(s) of the related party and/ nature of relationship: Yogesh Sachdeva **/ Key Management Personnel**

(b) Nature of contracts/arrangements/transactions: **Repayment of Loan**

(c) Duration of the contracts/arrangements/transactions: **Ongoing**

(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **311.15 Lakhs**

(e) Date(s) of approval by the Board, if any: 17.04.2025

(f) Amount paid as advances, if any: **N.A.**

(VII)

(a) Name(s) of the related party and/ nature of relationship: M. S. Medicals Private Limited / **Subsidiary Company**

(b) Nature of contracts/arrangements/transactions: **Loan Given**

(c) Duration of the contracts/arrangements/transactions: **Ongoing**

(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **559.70 Lakhs**

(e) Date(s) of approval by the Board, if any: 17.04.2025

(f) Amount paid as advances, if any: **N.A.**

(VIII)

(a) Name(s) of the related party and/ nature of relationship: M. S. Medicals Private Limited / **Subsidiary Company**

(b) Nature of contracts/arrangements/transactions: **Interest Received**

(c) Duration of the contracts/arrangements/transactions: **Ongoing**

(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **12.14 Lakhs**

(e) Date(s) of approval by the Board, if any: 17.04.2025

(f) Amount paid as advances, if any: **N.A.**

(IX)

(a) Name(s) of the related party and/ nature of relationship: M. S. Medicals Private Limited / **Subsidiary Company**

(b) Nature of contracts/arrangements/transactions: **Purchase of Goods**

(c) Duration of the contracts/arrangements/transactions: **Ongoing**

(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **47.03 Lakhs**

(e) Date(s) of approval by the Board, if any: 17.04.2025

(f) Amount paid as advances, if any: **N.A.**

(X)

(a) Name(s) of the related party and/ nature of relationship: Ayka Medical INC **/ Director's Relative is a Proprietor**

(b) Nature of contracts/arrangements/transactions: **Purchase of Goods**

(c) Duration of the contracts/arrangements/transactions: **Ongoing**

(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **4.78 Lakhs**
(e) Date(s) of approval by the Board, if any: 17.04.2025
(f) Amount paid as advances, if any: **N.A.**

(XI)

(a) Name(s) of the related party and/ nature of relationship: Organic wipes LLP **/ Director's Relative is designated Partner in LLP**
(b) Nature of contracts/arrangements/transactions: **Purchase of Goods**
(c) Duration of the contracts/arrangements/transactions: **Ongoing**
(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **67.29 Lakhs**
(e) Date(s) of approval by the Board, if any: 17.04.2025
(f) Amount paid as advances, if any: **N.A.**

(XII)

(a) Name(s) of the related party and/ nature of relationship: M. S. Medicals Private Limited / Subsidiary Company
(b) Nature of contracts/arrangements/transactions: **Sale of Goods**
(c) Duration of the contracts/arrangements/transactions: **Ongoing**
(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **1900.61 Lakhs**
(e) Date(s) of approval by the Board, if any: 17.04.2025
(f) Amount paid as advances, if any: **N.A.**

(XIII)

(a) Name(s) of the related party and/ nature of relationship: Sceptre Medical Devices Private Limited / Subsidiary Company
(b) Nature of contracts/arrangements/transactions: **Sale of Goods**
(c) Duration of the contracts/arrangements/transactions: **Ongoing**
(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **3.38 Lakhs**
(e) Date(s) of approval by the Board, if any: 17.04.2025
(f) Amount paid as advances, if any: **N.A.**

(XIV)

(a) Name(s) of the related party and/ nature of relationship: Ayka Medical Inc/ **Director's Relative is a Proprietor**
(b) Nature of contracts/arrangements/transactions: **Sale of Goods**
(c) Duration of the contracts/arrangements/transactions: Ongoing

(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **0.13 Lakhs**

(e) Date(s) of approval by the Board, if any: 17.04.2025

(f) Amount paid as advances, if any: **N.A.**

(XV)

(a) Name(s) of the related party and/ nature of relationship: Manocha Surgicals / **Director's Relative is a Proprietor**

(b) Nature of contracts/arrangements/transactions: **Sale of Goods**

(c) Duration of the contracts/arrangements/transactions: **Ongoing**

(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **2.41 Lakhs**

(e) Date(s) of approval by the Board, if any: 17.04.2025

(f) Amount paid as advances, if any: **N.A.**

(XVI)

(a) Name(s) of the related party and/ nature of relationship: Organic Wipes LLP / **Director's Relative is Designated Partner in LLP.**

(b) Nature of contracts/arrangements/transactions: **Sale of Goods**

(c) Duration of the contracts/arrangements/transactions: **Ongoing**

(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **92.27 Lakhs**

(e) Date(s) of approval by the Board, if any: 17.04.2025

(f) Amount paid as advances, if any: **N.A.**

(XVII)

(a) Name(s) of the related party and/ nature of relationship: Organic Wipes and Cosmetics/ **Director's Relative is Partner in firm**

(b) Nature of contracts/arrangements/transactions: **Sale of Goods**

(c) Duration of the contracts/arrangements/transactions: **Ongoing**

(d) Salient terms of the contracts or arrangements or transactions including the value, if any: **0.40 Lakhs**

(e) Date(s) of approval by the Board, if any: 17.04.2025

(f) Amount paid as advances, if any: **N.A.**

On behalf of Board of Directors,
For **Sceptre Medical (India) Limited**
(Formerly known as Sceptre Medical (India) Private Limited)

Sd/-	**Sd/-**	**Sd/-**	**Sd/-**
Sanjay Manocha	**Yogesh Sachdeva**	**Kartik Palta**	**Archna Manocha**
(Managing Director)	**(Whole Time Director)**	**(Whole Time Director)**	**(Director)**
DIN 00076997	**DIN: 00077095**	**DIN: 01543913**	**DIN: 02020796**

Date: 05.09.2026
Place: New Delhi

INDEPENDENT AUDITORS' REPORT

TO THE MEMBERS OF SCEPTRE MEDICAL (INDIA) LIMITED

Report on the Audit of Standalone Financial Statements

Opinion

We have audited the Standalone Financial Statements of **Sceptre Medical (India) Limited** ("*the Company*") which comprises the Standalone Balance Sheet as at March 31, 2026, the Standalone Statement of Profit and Loss and the Standalone Statement of Cash Flows for the year then ended and notes to the Standalone Financial Statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting standards prescribed under section 133 of the Act read with the Companies (Accounting Standards), Rules 2021 and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, its profits and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the standalone financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Information other than the Standalone Financial Statements and Auditors' Report thereon

The Company's management and board of directors is responsible for the preparation and presentation of the other information. The other information comprises the information included in the Annual Report including Annexures to Annual Report, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Responsibility of Management for the standalone financial statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibility for the Audit of the standalone financial statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure A statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143(3) of the Act, we report that:

   a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

   b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

   c) The Standalone Balance Sheet, Standalone Statement of Profit and Loss and Standalone Statement of Cash Flows dealt with by this Report are in agreement with the books of account.

   d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act.

   e) On the basis of the written representations received from the directors as on 31st March, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

   f) With respect to the adequacy of the internal financial controls over financial reporting with reference to the standalone financial statements of the

Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations which would impact its financial position.

ii. The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.

iii. There were no amounts which required to be transferred by the Company to the Investor Education and Protection Fund.

iv. a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

b) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

c) Based on such audit procedures that we have considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause iv(a) and iv(b) contain any material misstatement.

v. The company has not declared or paid dividend during the year.

vi. Based on our examination which included test checks, the company, in respect of financial year commencing on 1st April 2025, has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has been operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with and the audit trail has been preserved by the company as per the statutory requirements for record retention.

For SURENDER KUMAR SINGHAL & CO.
Chartered Accountants
FRN 009156N

Sd/-
CA Surender Singhal
Partner
M. N. 087072
Place: New Delhi
Date: 06.06.2026

UDIN: 26087072MJRVRQ2257

Annexure A to the Auditors' Report

[Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' of our Report of even date to the members of **SCEPTRE MEDICAL (INDIA) LIMITED** on the accounts of the company for the year ended **31st March, 2026**]

On the basis of such checks as we considered appropriate and according to the information and Explanations given to us during the course of our audit, we report that:

(i) In respect of the Company's Property, Plant and Equipment and Intangible Assets:

(a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of the Property, plant and equipment.

(B) The Company has maintained proper records showing full particulars of intangible assets during the year.

(b) As explained to us, Property, plant and equipment have been physically verified by the management during the year in accordance with the phased programme of verification adopted by the management which, in our opinion, provides for physical verification of all the Property, plant and equipment at reasonable intervals. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

(c) According to the information and explanations given to us and based on our examination of the records of the Company, the title deeds of all the immovable properties disclosed in the financial statements are held in the name of the Company as at the balance sheet date.

(d) The Company has not revalued any of its Property, Plant and Equipment and intangible assets during the year.

(e) No proceedings have been initiated during the year or are pending against the Company as at March 31, 2026 for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.

(ii) In respect of its inventory:

(a) As explained to us, the Company is engaged in the manufacturing and trading of goods. Accordingly, the inventories held by the Company primarily comprise raw materials, finished goods and traded goods, which have been physically verified by the Management at reasonable intervals. In our opinion and according to the information and explanations given to us, the frequency and procedures of such physical verification are reasonable and adequate having regard to the size of the Company and the nature of its business.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets.

In our opinion and according to the information and explanation given to us, the quarterly returns or statements filed by the company with Bank are in agreement with the books of account of the Company (except as disclosed in Note No. 35 of the financial statements).

(iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, during the year the Company has made investment in and granted unsecured loan to its subsidiary company.

(a) The Company has provided loan and made investment during the year. The details of such loan and investment are as under:

Particulars	**Aggregate amount of loan/ Investments made during the year**	**Balance outstanding as at 31st March 2025**
Loan granted -M S Medicals Private Limited (Subsidiary Company)	Rs. 559.70 Lakhs	Rs. 570.63 Lakhs
Investment made - M S Medicals Private Limited (Subsidiary Company)	Rs. 448.38 Lakhs	Rs. 448.38 Lakhs

(b) The Company has granted loan to its subsidiary company as stated above, during the year. In our opinion, having regard to the nature of the relationship between the Company and the subsidiary and the purpose for which the loan was granted, the terms and conditions of such loan are not prejudicial to the interest of the Company.

(c) In respect of the loan granted to the subsidiary company, no schedule of repayment of principal and payment of interest has been stipulated. Accordingly, we are unable to comment on the regularity of repayment of principal and payment of interest.

(d) Since no repayment schedule has been stipulated, there are no amounts overdue for more than ninety days.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, no loan falling due during the year has been renewed or extended or fresh loans granted to settle the over dues of existing loans given to the subsidiary company.

(f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion the Company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment except for the following loans or advances in the nature of loans to its related parties as defined in Clause (76) of Section 2 of the Companies Act, 2013:

Particulars	**Related Parties (Rs. in Lakhs)**
Aggregate of loans/advances in nature of loan - Repayable on demand (A)	559.70
Percentage of loans/advances in nature of loan to the total loans	98.03%

(iv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of the loans granted and investments made during the year.

(v) The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence, this clause of the Order is not applicable.

(vi) According to the information and explanations given to us, this clause is not applicable to the Company as the Central Government has not prescribed the maintenance of cost records under sub-section (1) of Section 148 of the Companies Act, 2013 in respect of the activities carried on by the Company.

(vii) In respect of statutory dues:

(a) In our opinion, the Company has generally been regular in depositing undisputed statutory dues, including Goods and Services tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other statutory dues applicable to it with the appropriate authorities.
There were no undisputed amounts payable in respect of Goods and Service tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other statutory dues in arrears as at March 31, 2026 for a period of more than six months from the date they became payable.

(b) According to the information and explanations given to us, there are no statutory dues referred to in sub-clause(a) that have been deposited with the appropriate authorities on account of any dispute.

(viii) There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).

(ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to banks or financial institutions or any other lender during the year.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or other lender.

(c) In our opinion and according to the information and explanations given to us by the management, the Company has obtained term loans during the year. The term loans were applied for the purposes for which the loans were obtained.

(d) According to the information and explanations given to us and on an overall examination of the balance sheet of the company, we report that no funds raised on short-term basis have been used for long-term purposes by the company.

(e) According to the information and explanations given to us and on an overall examination of the financial statements and records of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures. Further, the Company has not raised any loans during the year on the pledge of securities held in its subsidiaries, associates or joint ventures. Accordingly, reporting under clauses 3(ix)(e) and 3(ix)(f) of the Order is not applicable.

(x) a) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under this clause is not applicable.

b) During the year, the Company has made a private placement of equity shares. In our opinion, the requirements of Section 42 and Section 62 of the Companies Act, 2013 have been complied with and the funds raised have been utilized for the purposes for which they were raised.

(xi) (a) No fraud by the Company and no material fraud on the Company has been noticed or reported during the year.

(b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and up to the date of this report.

(c) According to the information and explanations given to us, during the year there are no whistle blower complaints received by the company during the year.

(xii) The Company is not a Nidhi Company and hence this clause is not applicable.

(xiii) In our opinion and according to the information and explanations given to us, all transactions with the related parties are in accordance with Section 188 of the Act, where applicable, and the requisite details have been disclosed in the standalone financial statements, as required by the applicable accounting standards. Further, based on the threshold limits prescribed under Section 177 of the Act, the provisions relating to Audit Committee are not applicable to the Company.

(xiv) In our opinion and according to the information and explanations given to us, the provisions relating to internal audit under Section 138 of the Companies Act, 2013 are not applicable to the Company. Accordingly, reporting under clause 3(xiv)(a) and 3(xiv)(b) of the Companies (Auditor's Report) Order, 2020 is not applicable.

(xv) In our opinion during the year the Company has not entered into any non-cash transactions with its Directors or persons connected with its directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.

(xvi) a) In our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a) of the Order is not applicable.

b) According to the information and explanations given to us and based on our examination of the records of the company, the Company has not conducted any Non-Banking Financial or Housing Finance activities without obtained a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934.

c) According to the information and explanations given to us and based on our examination of the records of the company, the Company is not a Core Investment Company as defined in the regulations made by Reserve Bank of India. Accordingly, this sub clause is not applicable to the Company.

d) In our opinion, there is no core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) and accordingly this sub clause is not applicable.

(xvii) In our opinion, there is no cash loss in the financial year and in the immediately preceding financial year.

(xviii) There has been a voluntary resignation of the statutory auditors during the year. We have taken into consideration the information and explanations provided by the management and the communications received from the outgoing auditors, while conducting our audit.

(xix) On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the standalone financial statements and our knowledge of the Board of directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

(xx) In our opinion and according to the information and explanations given to us, the provisions of Section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility are not applicable to the Company. Accordingly, reporting under clause 3(xx)(a) and 3(xx)(b) of the Companies (Auditor's Report) Order, 2020 is not applicable.

(xxi) According to the information and explanations given to us and based on our examination of the records of the Company, reporting under clause 3(xxi) of the Companies (Auditor's Report) Order, 2020 is not applicable in respect of the standalone financial statements of the Company. The Company has two subsidiaries and prepares consolidated financial statements in accordance with the provisions of the Companies Act, 2013. Accordingly, no reporting has been made under this clause.

For SURENDER KUMAR SINGHAL & CO.
Chartered Accountants
FRN 009156N

Sd/-

CA Surender Singhal
Partner
M. N. 087072
Place: New Delhi
Date: 06.06.2026

UDIN: 26087072MJRVRQ2257

Annexure B to the Auditors' Report

ANNEXURE TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF SCEPTRE MEDICAL (INDIA) LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")
(Referred to in paragraph 2(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We were engaged to audit the internal financial controls over financial reporting of **SCEPTRE MEDICAL (INDIA) LIMITED** ("the Company") as of March 31, 2026 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, "the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India".

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on "the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India"]. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of

Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial control systems over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of standalone financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and

(3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the standalone financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For SURENDER KUMAR SINGHAL & CO.
Chartered Accountants
FRN 009156N

Sd/-
CA Surender Singhal
Partner
M. N. 087072
Place: New Delhi
Date: 06.06.2026

UDIN: 26087072MJRVRQ2257

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Standalone Balance Sheet

₹ (In Lakhs)

	Particulars	Note No	As at 31.03.2026	As at 31.03.2025
I	**EQUITY AND LIABILITIES**			
1	**Shareholders' Funds**			
	(a) Share Capital	3	134.71	117.19
	(b) Reserves and Surplus	4	2565.83	1187.89
2	**Non-current liabilities**			
	(a) Long-Term Borrowings	5	1238.37	487.41
	(b) Deferred Tax Liabilities (net)	6	23.86	31.61
	(c) Long-Term Provisions	7	37.21	18.26
3	**Current liabilities**			
	(a) Short-Term Borrowings	8	778.81	379.31
	(b) Trade Payables	9		
	(A) Total outstanding dues of micro enterprises and small enterprises; and		187.44	169.61
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises		94.75	62.90
	(c) Other Current Liabilities	10	318.58	171.80
	(d) Short Term Provisions	11	169.20	109.60
	TOTAL		**5548.76**	**2735.59**
II.	**ASSETS**			
1	**Non Current Assets**			
	(a) Property, Plant and Equipment and Intangible assets			
	(i) Property, Plant and Equipment	12	1346.34	1288.75
	(ii) Intangible assets		0.10	0.21
	(iii) Capital Work-in-progress	13	474.55	-
	(b) Non-Current Investments	14	530.32	81.94
	(c) Other Non-Current Assets	15	62.07	68.31
2	**Current Assets**			
	(a) Inventories	16	596.57	711.97
	(b) Trade Receivables	17	1296.06	523.92
	(c) Cash and Cash Equivalents	18	445.20	24.18
	(d) Short Term Loans and Advances	19	753.57	21.54
	(e) Other Current Assets	20	43.98	14.77
	TOTAL		**5548.76**	**2735.59**

The accompanying notes form an integral part of financial statements

As per our report of even date attached

For Surender Kumar Singhal & Co.
Chartered Accountants
Firm Reg No.: 009156N

Sd/-
CA. Surender Singhal
Partner
M.No. 087072

Place: New Delhi
Date:

For and on behalf of Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director
DIN:00077095

Sd/-
Archna Manocha
Director & CFO
DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Standalone Statement of Profit & Loss

₹ (In Lakhs)

	Particulars	Note No.	For the year ended 31.03.2026	For the year ended 31.03.2025
	Income:			
I	Revenue from operations	21	4778.99	2869.45
II	Other Income	22	49.94	6.09
III	**Total Income (I+II)**		**4828.93**	**2875.54**
IV	**Expenses:**			
	Cost of materials consumed	23	2427.77	1347.97
	Purchases of Stock-in-Trade	24	183.77	408.42
	Changes in Inventories of finished goods and Stock-in-Trade	25	57.70	(98.91)
	Employee Benefits Expense	26	574.68	365.43
	Finance Costs	27	98.20	64.77
	Depreciation and Amortization Expense	28	72.24	70.07
	Other Expenses	29	324.16	236.96
IV	**Total expenses**		**3738.52**	**2394.72**
V	**Profit before exceptional and extraordinary items and tax (III - IV)**		1090.41	480.82
VI	**Exceptional Items**		-	-
VII	**Profit before tax (V-VI)**		1090.41	480.82
VIII	**Tax expense:**			
	(1) Current Tax		257.77	125.00
	(2) Deferred Tax		(7.75)	(35.28)
IX	**Profit (Loss) for the period (V-VI)**		840.39	391.10
X	**Earning per equity share:**	30		
	(a) Basic (in Rs.)		66.45	33.37
	(b) Diluted (in Rs.)		66.45	33.37

The accompanying notes form an integral part of financial statements

As per our report of even date

For Surender Kumar Singhal & Co.
Chartered Accountants
Firm Reg No.: 009156N

Sd/-
CA. Surender Singhal
Partner
M. No. 087072
Place: New Delhi
Date:

For and on behalf of Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director
DIN:00077095

Sd/-
Archna Manocha
Director & CFO
DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

Sceptre Medical (India) Limited
(formerly known as "Sceptre Medical (India) Private Limited")
Standalone Cash Flow Statement

₹ (In Lakhs)

Particulars	For the year ended 31.03.2026	For the year ended 31.03.2025
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit Before Extraordinary Items	1090.41	480.82
Adjustment For:		
(A) Depreciation And Amortization Expense	72.24	70.07
(B) Finance Charges	98.20	64.77
(C) Provision For Gratuity And Leave Encashment	20.12	18.71
(E) Profit on sale of fixed Assets	(5.42)	(0.04)
(F) Interest on FDR	(2.41)	(2.29)
(G) Loss on sale of investments	-	14.16
Operating Profit Before Working Capital Changes	1273.14	646.20
Adjustment For:		
(A) (Increase)/Decrease In Inventories	115.40	(298.32)
(B) (Increase)/Decrease In Trade Receivables	(772.14)	(52.48)
(C) (Increase)/Decrease In Loans & Advances	(732.04)	17.01
(D) (Increase)/Decrease In Other Assets	(29.21)	(8.45)
(E) Increase /(Decrease) In Trade Payables	49.67	139.67
(F) Increase /(Decrease) in Other Liabilities & Provisions	146.78	49.38
Cash generated from operations	51.61	493.01
Less: Direct Taxes Paid (Net Of Refund)	242.91	76.66
Net Cash generated from Operating Activities (A)	**(191.30)**	**416.35**
B. CASH FLOW FROM INVESTING ACTIVITIES		
(A) Purchase of property plant & equipment including capital work-in-progress	(619.71)	(563.56)
(B) Sale of Fixed Assets	15.45	0.06
(C) Profit on sale of fixed assets	5.42	0.04
(D) Loss on Sale of Fixed assets	-	(14.16)
(E) (Increase)/ Decrease In Investment	(448.38)	215.23
(F) (Increase)/ Decrease In Non-Current Assets	6.24	(52.63)
(G) Interest And Other Income	2.41	2.29
Net Cash generated from Investing Activities (B)	**(1038.58)**	**(412.73)**
C. Cash Flow From Financing Activities		
(A) Proceeds/(Repayment) of Long-Term Borrowings	750.96	(146.49)
(B) Proceeds/(Repayment) of Short-Term Borrowings	399.50	184.05
(C) Interest Paid	(98.20)	(64.77)
(D) Issue of new Equity Shares	598.64	-
Net Cash generated from Financing Activities (C)	**1650.90**	**(27.21)**
Net Increase In Cash & Cash Equivalents (A)+(B)+(C)	421.02	(23.59)
Opening Balance – Cash & Cash Equivalents	24.18	47.76
Closing Balance - Cash & Cash Equivalents	**445.20**	**24.18**

As per our report of even date

For Surender Kumar Singhal & Co.
Chartered Accountants
Firm Reg No.: 009156N

Sd/-
CA. Surender Singhal
Partner
M. No. 087072
Place: New Delhi
Date:

For and on behalf of Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director

Sd/-
Archna Manocha
Director & CFO

DIN:00077095 DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

Sceptre Medical (India) Limited
(formerly known as "Sceptre Medical (India) Private Limited")
Notes forming part of the Standalone Financial Statements for the year ended 31.03.2026

1 Corporate Information

Sceptre Medical (India) Limited ("the Company") was originally incorporated on 24th June, 2010 under the provisions of the Companies Act, 1956 as a Private Limited Company. Subsequently, the Company was converted into a Public Limited Company pursuant to the applicable provisions of the Companies Act, 2013, and its name was changed to Sceptre Medical (India) Limited with effect from 21st January, 2026.

The Company is engaged in the business of manufacturing, trading and distribution of medical devices, infection control products, disinfectants and hygiene solutions, including wet wipes for healthcare, institutional and personal care applications. The Company operates manufacturing facilities in Haryana and caters to hospitals, healthcare institutions, dialysis centres and retail customers through its distribution network across India.

The Company has two subsidiaries, namely Sceptre Medical Devices Private Limited and M S Medical Private Limited, engaged in the healthcare and medical consumables segments.

2 Significant Accounting Policies

2.1 Basis of Preparation of Financial Statements

The financial statements of the Company have been prepared in accordance with the generally accepted accounting principles in India ("Indian GAAP") and comply, in all material respects, with the Accounting Standards notified under Section 133 of the Companies Act, 2013 and the Companies (Accounting Standards) Rules, 2021.The financial statements have been prepared on an accrual basis and under the historical cost convention. The accounting policies have been applied consistently.

2.2 Current / Non-Current Classification:

Any asset or liability is classified as current if it satisfies any of the following conditions:

i. the asset/liability is expected to be realised/settled in the Company's normal operating cycle;
ii. the asset is intended for sale or consumption;
iii. the asset/liability is held primarily for the purpose of trading;
iv the asset/liability is expected to be realised/ settled within twelve months after the reporting period;
the asset is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for
v at least twelve months after the reporting date;
vi in the case of a liability, the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

All other assets and liabilities are classified as non-current.

Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current – non- current classification of assets and liabilities.

2.3 Investment in Subsidiaries

During the Financial Year 2025-26, the Company owned two subsidiaries, namely Sceptre Medical Devices Private Limited and M S Medicals Private Limited, engaged in the healthcare and medical consumables segments.

Sceptre Medical Devices Private Limited

During the Financial Year 2024-25, the company had acquired 40% of Sceptre Medical Devices Private Limited making it associate company. On 30th March 2026, it became subsidiary company pursuant to the acquisition of control by the holding company through the right to appoint and control the majority of the Board of Directors.

M S Medicals Private Limited

On 1st April, 2025, the company has acquired 100% shares of M S Medicals Private Limited, making it wholly owned subsidiary.

Accordingly, these investments have been accounted for in the Standalone Financial Statements in accordance with Accounting Standard (AS) 13 – *Accounting for Investments*, notified under the Companies (Accounting Standards) Rules, 2006 read with the Companies Act, 2013

2.4	**Use of Estimates and Judgements** In preparation of the financial statements, the Company is required to make judgments, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and the associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and the underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods affected significant judgments and estimates about the carrying amount of assets and liabilities include useful lives of tangible assets, impairment of Tangible assets, investments, employee benefits and other provisions and recoverability of deferred tax assets.
2.5	**Functional and presentation currency** These Financial Information are presented in Indian Rupees (₹), which is also its functional currency. All amounts have been rounded off to two decimal places to the nearest lakhs, unless otherwise indicated. Amount less than ₹ 1,000 have been presented as "0.00"
2.6	**Property, Plant and Equipment and Intangible Assets** Property, Plant and Equipment are stated at cost less accumulated depreciation and impairment losses, if any. Cost comprises of all expenses incurred to bring the assets to its present location and condition. Borrowing cost directly attributable to the acquisition /construction are included in the cost of fixed assets. Adjustments arising from exchange rate variations attributable to the fixed assets are capitalized. The company has adopted cost model for all class of items of Property, Plant and Equipment. In case of new projects / expansion of existing projects, expenditure incurred during construction / preoperative period including interest and finance charge on specific / general purpose loans, prior to commencement of commercial production are capitalized. The same are allocated to the respective on completion of construction / erection of the capital project / fixed assets. Subsequent expenditures related to an item of tangible asset are added to its book value only if they increase the future economic benefits from the existing asset beyond its previously assessed standard of performance. Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective individual estimated useful lives on a Straight line method, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors, including the effects of obsolescence, demand, competition, and other economic factors (such as the stability of the industry, and known technological advances), and the level of maintenance expenditures required to obtain the expected future cash flows from the asset. Amortization methods and useful lives are reviewed periodically including at each financial year end.
2.7	**Borrowing Cost** Borrowing costs include interest, other costs incurred in connection with borrowing and exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to the interest cost. General and specific borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognized in Statement of Profit and Loss in the period in which they are incurred.
2.8	**Impairment of Assets** The Management periodically assesses using external and internal sources, whether there is an indication that an asset may be impaired. An impairment loss is recognized wherever the carrying value of an asset exceeds its recoverable amount. The recoverable amount is higher of the asset's net selling price and value in use, which means the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. An impairment loss for an asset is reversed only when the reversal can be related objectively to an event occurring after the impairment loss was recognized. The carrying amount of an asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation had no impairment loss been recognized for the asset in prior years). As per Accounting Standard (AS-28) impairment of assets the company has carried the Impairment test during the year. There is no material impairment loss in the carried cost in the assets in the books and the recoverable amount is not lower than the carrying amount in the accounts.

2.9 Inventories

As per (AS) 2, the inventories are physically verified at regular intervals by the management. Inventories comprising raw materials, finished goods and stock-in-trade are valued at the lower of cost and net realisable value. Cost of raw materials and stock-in-trade includes purchase cost and related expenses and is determined on FIFO basis. Cost of finished goods includes raw materials, direct labour and applicable overheads.

2.10 Foreign Currency Transactions

Conversion

Foreign currency monetary items are reported using the closing rate.
Non-monetary items, which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction.

Exchange Differences

Exchange differences arising on the settlement or reporting of monetary items at rates different from those at which they were initially recorded during the year, or reported in previous audited financial statement, are recognized as income or expense in the Statement of Profit and Loss.

2.11 Cash and Cash equivalents

Cash comprises cash on hand and demand deposits with banks, Cash equivalents are short term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

2.12 Depreciation and amortization

Depreciation on Fixed Assets is provided on Straight Line Method (SLM), over the estimated useful life of the Assets in the manner prescribed in Schedule II of the Act.
Depreciation on additions to assets or on sale / discernment of assets, is calculated prorate basis from the month of such addition or up to the month of such sale/discardment, as the case may be.

2.13 Cash Flow Statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financial activities of the company are segregated based on the available information.

2.14 Revenue Recognition

Revenue from the operations is recognized on generally accepted accounting principal and when it is earned and no significant uncertainty exists as to its ultimate collection and includes taxes, wherever applicable.

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The capital gain on sale of investments if any are recognized on completion of transaction. No notional profit/loss are recognized on such investments. Interest income is recognized on time proportion basis, when it is accrued and due for payment.

2.15 Employee Benefits

i) Defined Contribution Plans: Contributions to the employees' regional Provident Fund, Employees Pension Scheme and Employees' State Insurance are recognized as defined contribution plan and charged as expenses during the period in which the employees perform the services. The Company has no obligation, other than the contribution payable to the respective funds.

ii) Defined Benefit Plans : Retirement benefits in the form of Gratuity and Leave Encashment are considered as defined benefit plan and determined on actuarial valuation using the Projected Unit Credit Method at the balance sheet date. Actuarial Gains or Losses through re-measurement of the net obligation of a defined benefit liability or asset is recognized in Profit and Loss account.

2.16	**Current and deferred tax** Tax expense for the period, comprising current tax and deferred tax, are included in the determination of the net profit or loss for the period. Current tax is measured at the amount expected to be paid to the tax authorities in accordance with the taxation laws prevailing in the respective jurisdictions. Deferred tax is recognised for all the timing differences, subject to the consideration of prudence in respect of deferred tax assets. Deferred tax assets are recognised and carried forward only to the extent that there is a reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. Deferred tax assets and liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted on the Balance Sheet date. In situations, where the Company has unabsorbed depreciation or carry forward losses under tax laws, all deferred tax assets are recognised only to the extent that there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits. At each Balance Sheet date, the Company re-assesses unrecognised deferred tax assets, if any. Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle the asset and the liability on a net basis. Deferred tax assets and deferred tax liabilities are offset when there is a legally enforceable right to set off assets against liabilities representing current tax and where the deferred tax assets and the deferred tax liabilities relate to taxes on income levied by the same governing taxation laws
2.17	**Provisions and Contingent Liabilities** Provisions: Provisions are recognised when there is a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance sheet date and are not discounted to its present value. Contingent Liabilities: Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non occurrence of one or more uncertain future events not wholly within the control of the company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made. No such events occurred during the year.
2.18	**Earning Per Share** Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Earnings considered in ascertaining the Company's earnings per share is the net profit for the period after deducting any attributable tax thereto for the period. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average numbers of shares outstanding during the period is adjusted for the effects of all new equity shares issued during the year.
2.19	The previous year figures have been regrouped / reclassified, wherever necessary to confirm to the current year presentation

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Notes on Standalone Financial Statements

Note No. 3: Share Capital **₹ (In Lakhs)**

Particulars	As at 31.03.2026	As at 31.03.2025
Authorized Share Capital :		
2,50,00,000 Equity shares of Rs.10/- each	2500.00	200.00
(Previous Year 20,00,000 Equity Shares)		
Issued, Subscribed and Paid up :		
13,47,062 Equity Shares of Rs.10/- each fully paid up	134.71	117.19
(Previous Year 11,71,944 Equity Shares of Rs.10/- each)		
Total	**134.71**	**117.19**

The Reconciliation of the numbers of shares outstanding is set out below:

Authorised Share Capital **₹ (In Lakhs)**

	31.03.2026		31.03.2025	
Particulars	**No. of Shares**	**Amount**	**No. of Shares**	**Amount**
Opening Share Capital	2,000,000	200.00	2,000,000	200.00
Add: Increased during the year	23,000,000	2300.00	-	-
Closing Share Capital	25,000,000	2500.00	2,000,000	200.00

Issued, Subscribed and Paid up

	31.03.2026		31.03.2025	
Particulars	**No. of Shares**	**Amount**	**No. of Shares**	**Amount**
Opening Share Capital	1,171,944	117.19	1,171,944	117.19
Add: Shares issued During the year	175,118	17.51	-	-
Closing Share Capital	1,347,062	134.71	1,171,944	117.19

Details of Shareholders holding more than 5% Shares:

	31.03.2026		31.03.2025	
Particulars	**No. of Shares**	**% held**	**No. of Shares**	**% held**
Name of the Shareholders				
Sanjay Manocha	292,986	21.75	292,986	25.00
Archna Manocha	135,167	10.03	135,167	11.53
Kartik Palta	169,931	12.61	169,931	14.50
Yogesh Sachdeva	234,389	17.40	234,389	20.00
Sukesh Arora	140,633	10.44	140,633	12.00
Mona Sachdeva	93,756	6.96	93,756	8.00
Charu Palta	64,457	4.79	64,457	5.50

The details of Shareholding of Promoters:

	31.03.2026		31.03.2025	
Particulars	**No. of Shares**	**% held**	**No. of Shares**	**% held**
Name of the Shareholders				
Sanjay Manocha	292,986	21.75	292,986	25.00
Archna Manocha	135,167	10.03	135,167	11.53
Kartik Palta	169,931	12.61	169,931	14.50
Yogesh Sachdeva	234,389	17.40	234,389	20.00
Sukesh Arora	140,633	10.44	140,633	12.00
Mona Sachdeva	93,756	6.96	93,756	8.00
Charu Palta	64,457	4.79	64,457	5.50
Siddharth Manocha	40,625	3.02	40,625	3.47

Terms/rights attached to Equity Shares

The company has only one class of equity shares having a par value of Rs.10 per share. All these shares have same rights and preferences with respect to payment of dividend, repayment of capital and voting.

During the year, the Company has issued 1,21,235 equity shares of ₹ 10 each at a premium of ₹ 154 per share, 53,883 equity shares of ₹ 10 each at a premium of ₹ 732 per share aggregating to ₹ 598.64 lakhs (including securities premium of ₹ 581.13 lakhs) for cash consideration.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

Note No. 4: Reserves And Surplus **₹ (In Lakhs)**

Particulars	As at 31.03.2026	As at 31.03.2025
Securities Premium		
Opening Balance	82.50	82.50
Add: Shares issued during the year	581.13	-
Total (A)	**663.63**	**82.50**
Profit & Loss Account		
Opening Balance	1105.38	714.90
Add: Profit for the year	840.39	391.10
Add: Prior period adjustments*	(43.57)	(0.61)
Total (B)	**1902.20**	**1105.38**
Grand Total (A+B)	**2565.83**	**1187.89**

*Prior period tax adjustments relating to earlier years have been adjusted directly against the balance of Reserves & Surplus during the year and accordingly have not been recognised in the current year's Statement of Profit & Loss.

Sceptre Medical (India) Limited
(formerly known as "Sceptre Medical (India) Private Limited")
Notes on Standalone Financial Statements

₹ (In Lakhs)

Particulars	As at 31.03.2026	As at 31.03.2025
Note No. 5: Long Term Borrowings		
Secured		
From Banks		
(i) Term Loans	1445.63	714.75
	1445.63	714.75
Less: current maturities of long-term borrowings		
(i) Term Loans	207.26	227.34
	207.26	227.34
Total	**1238.37**	**487.41**
Note No. 6: Deferred Tax Liabilities		
On account of difference between tax value and book value	23.86	31.61
Total	**23.86**	**31.61**
Note No. 7: Long Term Provisions		
Provision for Gratuity	29.54	16.68
Provision for Leave Encashment	7.68	1.59
Total	**37.21**	**18.26**
Note No. 8: Short Term Borrowings		
Secured		
(A) from banks		
(i) Cash credit	471.55	-
(ii) Current Maturities of Long Term Borrowings;		
- Term Loans	207.26	227.34
Unsecured		
(A) from banks		
(i) Working Capital Loan	100.00	-
(B) Loan from Related Parties	-	151.97
Total	**778.81**	**379.31**
Note No. 9: Trade Payables		
Due to Micro and Small enterprises	187.44	169.61
Due to Others	94.75	62.90
Total	**282.18**	**232.51**
Note No. 10: Other Current Liabilities		
Statutory Dues Payable	9.15	56.07
Salary Payable	36.05	34.30
Expenses Payable	33.02	29.36
Other Current Liabilities	86.66	52.07
Advance From Customers	73.71	-
Advance against property	80.00	
Total	**318.58**	**171.80**
Note No. 11: Short Term Provisions		
Provision for Income Tax	167.58	109.15
Provision for Gratuity	0.80	0.35
Provision for Leave Encashment	0.82	0.10
Total	**169.20**	**109.60**

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Terms & Conditions of Loans for Note No. 5 & 8

Loan account Number	Lender	Nature of facility	Sanctioned Amount (₹ in Lakhs)	Outstanding as on March 31, 2026 (₹ in Lakhs)	Rate of Interest / Margin	Repayment Terms	Security/ Principal terms and conditions
050210SZ00000014	PNB	Term Loan	92.70	59.58	8.65%	Repayable in 24 EMI of ₹ 370000*23, ₹ 389034*1	Mortgage Plot No. 230-31
050210CN00000117	PNB	Term Loan	28.62	17.52	8.40%	Repayable in 15 EMI of ₹ 185000*14, ₹ 86,691*1	Mortgage Plot No. 230-31
050210CN00000135	PNB	Term Loan	105.68	89.05	8.40%	Repayable in 37 EMI of ₹ 277000*36, ₹ 318323*1	Mortgage Plot No. 230-31
050210CN00000126	PNB	Term Loan	162.00	142.49	8.40%	Repayable in 49 EMI of ₹ 325000*48, ₹ 274163*1	Mortgage Plot No. 230-31
050210CN00000108	PNB	Term Loan	186.00	150.99	8.40%	Repayable in 28 EMI of ₹ 550000*1, ₹ 600000*12, ₹ 675000*12, ₹ 750000*2 , ₹ 698166*1	Mortgage Plot No. 230-31
D000ELKE	SIDBI	Term Loan	1700.00	986.00	8.10%	Repayable in 84 EMI of ₹ 2361000*83, ₹ 2369000*1	Mortgage Khewat No. 100, Killa No.19/5 (Liwan)
GST SAHAY	SIDBI	Bill Discounting	100.00	100.00	9.50%	-	Unsecured Loan
D000380Z	SIDBI	Term Loan	370.00	-	10.10%	Repayable in 72 EMI of ₹ 250000*6, ₹ 300000*6, ₹ 350000*12, ₹ 450000*12 , ₹ 550000*12, ₹ 600000*12, ₹ 675000*12, ₹ 750000*2, ₹ 700000*1	Mortgage Plot No. 230-231
D0003CPP	SIDBI	Term Loan	81.00	-	8.45%	Repayable in 36 EMI of ₹ 225000*36	Mortgage Plot No. 230-31
D0003ZTA	SIDBI	Term Loan	100.00	-	8.40%	Repayable in 54 EMI of ₹ 185000*53, ₹ 195000*1	Mortgage Plot No. 230-31
D000547D	SIDBI	Term Loan	200.00	-	8.45%	Repayable in 54 EMI of ₹ 370000*53, ₹ 390000*1	Mortgage Plot No. 230-31
D000BGA6	SIDBI	Term Loan	175.00	-	8.66%	Repayable in 54 EMI of ₹ 325000*53, ₹ 275000*1	Mortgage Plot No. 230-31
D00082XV	SIDBI	Term Loan	150.00	-	8.40%	Repayable in 54 EMI of ₹ 277000*53, ₹ 319000*1	Mortgage Plot No. 230-31

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Note 9.1 **Trade payables ageing schedule for the year:**

Outstanding for following periods from due date of payment (2025-26)

₹ (In Lakhs)

S. No	Particulars	Not due	Unbilled amount	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
	MSME	-	-	187.26	0.18	-	-	187.44
	Others	-	-	94.16	0.59	-	-	94.75
	Disputed dues-MSME	-	-	-	-	-	-	-
	Disputed dues-Others	-	-	-	-	-	-	-
	Total	**-**	**-**	**281.41**	**0.77**	**-**	**-**	**282.18**

Outstanding for following periods from due date of payment (2024-25)

₹ (In Lakhs)

S. No	Particulars	Not due	Unbilled amount	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
	MSME	-	-	168.03	1.58	-	-	169.61
	Others	-	-	62.90	-	-	-	62.90
	Disputed dues-MSME	-	-		-	-	-	-
	Disputed dues-Others	-	-		-	-	-	-
		-	**-**	**230.93**	**1.58**	**-**	**-**	**232.51**

For and on behalf of the Board

Sanjay Manocha
Managing Director
DIN:00076997

Kartik Palta
Whole Time Director
DIN:01543913

Yogesh Sachdeva
Whole Time Director
DIN:00077095

Archna Manocha
Director & CFO
DIN:02020796

Vidushi
Company Secretary
M. No. A71077

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Note 17.1 **Trade receivables ageing schedule for the year:**

Outstanding for following periods from due date of payment (2025-26)

₹ (In Lakhs)

S.no	Particulars	Not due	Unbilled amount	Less Than 6 months	6month-1 years	1-2 years	2-3 years	More than 3 years	Total
	Undisputed Trade Receivables – considered good	-	-	869.28	124.99	301.80	-	-	129,605,945.86
	Undisputed Trade Receivables – considered Doubtful	-	-	-		-	-	-	-
	Disputed Trade Receivables – considered good	-	-	-	-	-	-	-	-
	Disputed Trade Receivables – considered Doubtful	-	-	-	-	-	-		
	Total	-	-	869.28	124.99	301.80	-	-	1296.06

Outstanding for following periods from due date of payment (2024-25)

₹ (In Lakhs)

S.no	Particulars	Not due	Unbilled amount	Less Than 6 months	6month-1 years	1-2 years	2-3 years	More than 3 years	Total
	Undisputed Trade Receivables – considered good	-	-	509.84	1.16	2.46	-	10.47	523.92
	Undisputed Trade Receivables – considered Doubtful	-	-	-	-	-	-	-	-
	Disputed Trade Receivables – considered good	-	-	-	-	-	-	-	-
	Disputed Trade Receivables – considered Doubtful	-	-	-	-	-	-	-	-
	Total	-	-	509.84	1.16	2.46	-	10.47	523.92

For and on behalf of the Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director
DIN:00077095

Sd/-
Archna Manocha
Director & CFO
DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Note No. 12 Property, Plant and Equipment and Intangible assets

Financial Year 2025-26

₹ (In Lakhs)

Particulars	Original Cost				Depreciation				Net Book Value	
	As at 01.04.2025	Addition	Deletion	As at 31.03.2026	As at 01.04.2025	For the Year	Adjusted	Total 31.03.2026	As at 31.03.2026	As at 31.03.2025
PROPERTY, PLANT AND EQUIPMENT :										
Land	679.99	18.04	4.72	693.31	-	-	-	-	693.31	679.99
Factory Building	245.02	-	-	245.02	54.04	7.77	-	61.81	183.22	190.98
Plant & Machinery	429.35	112.17	16.79	524.73	145.94	29.40	6.24	169.11	355.62	283.41
Computer	18.15	8.19	-	26.34	14.59	2.84	-	17.43	8.91	3.55
Furniture & Fixture	63.70	2.59	-	66.29	21.37	5.94	-	27.31	38.98	42.33
Office Equipment	73.69	4.18	-	77.87	47.16	11.18	-	58.35	19.53	26.53
Vehicles	147.78	-	8.50	139.28	85.83	15.00	8.33	92.50	46.78	61.96
Total (A)	**1657.68**	**145.16**	**30.01**	**1772.84**	**368.93**	**72.13**	**14.56**	**426.50**	**1346.34**	**1288.75**
INTANGIBLE ASSETS:										
Softwares	1.92	-	-	1.92	1.71	0.11	-	1.83	0.10	0.21
Total (B)	**1.92**	**-**	**-**	**1.92**	**1.71**	**0.11**	**-**	**1.83**	**0.10**	**0.21**
Grand Total (A+B)	**1659.60**	**145.16**	**30.01**	**1774.76**	**370.64**	**72.24**	**-**	**428.32**	**1346.44**	**1288.96**
Previous Year	*1097.18*	*563.56*	*1.14*	*1659.60*	*301.65*	*70.07*	*-*	*370.64*	*1288.96*	*795.53*

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Notes on Standalone Financial Statements

₹ (In Lakhs)

Particulars	As at 31.03.2026	As at 31.03.2025
Note No. 13: Capital Work-in-Progress		
Building under construction	474.55	-
(Factory at Liwan, Sonipat, Haryana)		
	474.55	**-**
Note No. 14: Non Current Investments		
Investment in Subsidiaries		
Investment in equity instrument-unquoted		
Investment measured at Cost		
3,72,000 (31 March 2025: 372000) Fully paid equity shares of Sceptre Medical Devices Private Limited of Rs. 10 each	81.94	81.94
9,54,000 (31 March 2025: 0) Fully paid equity shares of M S Medicals Private Limited of Rs. 10 each	448.38	-
Total	**530.32**	**81.94**
Note No. 15: Other Non Current Assets		
Unsecured, considered good		
Security Deposits	23.07	33.81
FDR with Banks	39.00	34.50
Total	**62.07**	**68.31**
Note No. 16: Inventories		
Raw Material	500.80	558.50
Stock-in-Trade	0.03	6.93
Finished Goods	95.74	146.54
Total	**596.57**	**711.97**
Note No. 17: Trade Receivables		
Secured, Considered good	**-**	**-**
Unsecured, considered good	1296.06	523.92
Doubtful	-	-
Total	**1296.06**	**523.92**
Note No. 18: Cash And Cash Equivalents		
Balance with Banks		
-In Current Accounts	433.62	20.32
-FDR with Banks	3.17	-
Cash on Hand	8.40	3.86
Total	**445.20**	**24.18**
Note No. 19: Short Term Loans & Advances		
[Unsecured-Considered Good (Unless Otherwise Stated)]		
Loan to subsidiary company		
- M S Medicals Private Limited	570.63	-
Advance against Capital Goods	156.11	-
Advance Against Purchase	26.50	3.83
Staff Advance	0.33	17.71
Total	**753.57**	**21.54**
Note No. 20: Other Current Assets		
VAT Refundable	-	1.05
GST Cash Ledger	0.10	0.12
GST Input Credit	5.24	2.44
GST Input Reco	5.32	8.83
GST Refund Receivable	29.77	-
IT Refund Receivable	-	1.34
Prepaid Expenses	3.56	0.98
Total	**43.98**	**14.77**

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Note 13.1 Capital Work-in-Progress ageing schedule for the year (2025-26): **₹ (In Lakhs)**

S. No.	Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
1	Building under construction	474.55	-	-	-	474.55 -
	Total	**474.55**	**-**	**-**	**-**	**474.55**

Capital Work-in-Progress ageing schedule for the year (2024-25):

S. No.	Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
1	Building under construction	-	-	-	-	- -
	Total	**-**	**-**	**-**	**-**	**-**

For and on behalf of the Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director
DIN:00077095

Sd/-
Archna Manocha
Director & CFO
DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

Sceptre Medical (India) Limited
(formerly known as "Sceptre Medical (India) Private Limited")
Notes on Standalone Financial Statements

₹ (In Lakhs)

Particulars	For the year ended 31.03.2026	For the year ended 31.03.2025
Note No. 21: Revenue From Operations		
Sale of Products	4948.05	2941.61
Less: Inter Unit Transfer	169.05	72.16
Total	**4778.99**	**2869.45**
Note:21.1		
(i) Sale of products comprises following:		
Domestic sales	4702.06	2833.78
Export sales	76.93	35.67
Total	**4778.99**	**2869.45**
Note No. 22: Other Income		
Interest on FDR	2.41	2.29
Reimbursement-Govt. Schemes	-	3.75
Interest on loans & advances	12.14	-
Interest on income tax refund	0.19	-
GST refund	29.77	-
Profit on sale of fixed assets	5.42	0.04
Total	**49.94**	**6.09**
Note No. 23: Cost Of Materials Consumed		
Add: Inventories at the beginning of the Year	558.50	359.10
Add: Purchase during the year	2371.30	1547.38
	2929.80	1906.48
Less: Inter unit transfer	1.23	-
Less: Inventories at the end of the Year	500.80	558.50
Total	**2427.77**	**1347.97**
Note No. 24: Purchase Of stock-in-trade		
Purchases of goods	351.59	480.58
Less: Inter unit transfer	167.82	72.16
Total	**183.77**	**408.42**
Note No. 25: Changes In inventories of finished goods and stock-in-trade		
Stock-in-trade		
Inventories at the end of the Year	0.03	6.93
Inventories at the beginning of the Year	6.93	27.81
Change in stock-in-trade (A)	**6.90**	**20.88**
Finished Goods		
Inventories at the end of the Year	95.74	146.54
Inventories at the beginning of the Year	146.54	26.75
Change in finished goods (B)	**(50.80)**	**119.79**
Total (C=A+B)	**57.70**	**(98.91)**
Note No. 26: Employee Benefits Expense		
Directors' Remuneration	146.73	82.80
Salary, Wages & Incentives	382.96	244.45
Contribution to Provident and other funds	14.37	16.54
Provision for Gratuity	14.46	17.02
Provision for Leave Encashment	9.48	1.69
Staff Welfare Expenses	6.68	2.93
Total	**574.68**	**365.43**

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Notes on Standalone Financial Statements

₹ (In Lakhs)

Particulars	For the year ended 31.03.2026	For the year ended 31.03.2025
Note No. 27: Finance Costs		
Bank Charges	23.74	0.89
Bank Interest	74.46	63.88
Total	**98.20**	**64.77**
Note No. 28: Depreciation And Amortization Expenses		
On Tangible & Intangible Assets	72.24	70.07
Total	**72.24**	**70.07**
Note No. 29: Other Expenses		
Audit Fee	3.50	1.25
Custom Duty	1.96	0.62
Clearing & Forwarding Charges	1.28	0.58
Foreign Exchange Fluctuation	1.81	0.05
Power & Fuel	35.92	25.55
Repair & Maintenance Expenses	22.86	15.81
Rent	28.30	20.82
Freight & Courier Charges	34.63	26.82
Job Work Charges	4.96	-
Conveyance & Travelling Expenses	51.18	33.46
Communication Expense	1.97	1.23
Office Expenses	3.98	4.98
Printing & Stationery Expenses	9.99	4.06
GST Expenses	0.39	5.16
Insurance Expenses	1.87	4.43
Fees & Taxes	4.07	2.65
Loss on sale of Investment	-	14.16
Professional Fee	36.48	25.69
Testing fee	7.61	3.72
Business Promotion Expenses	39.93	13.60
Discount Allowed	11.44	21.15
Commission	2.82	0.07
Security Charges	4.76	5.18
Festival Expenses	6.45	1.44
Website Expenses	3.32	4.26
Miscellaneous Expenses	2.68	0.21
Total	**324.16**	**236.96**
Note No. 29.1: Payment made to auditors (inclusive of taxes)		
For Statutory Audit	2.95	1.18
For Taxation Matters	1.18	0.30
	4.13	1.48

Note No. 30: Earning Per Equity Share

₹ (In Lakhs)

Particulars	For the year ended 31.03.2026	For the year ended 31.03.2025
1.Net Profit after tax as per Statement of Profit and Loss attributable to Equity Shareholders (₹ in Lakhs)	840.39	391.10
2. Weighted Average number of equity shares used as denominator for calculating EPS	1,264,725	1,171,944
3. Weighted Average number of equity shares used as denominator for calculating EPS Post Bonus	1,264,725	1,171,944
4. Basic Earnings per Share (In ₹) (On Face value of ₹ 10/ per share)	66.45	33.37
5. Diluted Earnings per Share (In ₹) (On Face value of ₹ 10/ per share)	66.45	33.37

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Note No. 31: 'Disclosure Regarding analytical ratios:

	Ratio	Numerator	Denominator	Current Period	Previous Period	% Variance	Reason for variance
1	Current Ratio (in times)	Current Assets	Current Liabilities	2.02	1.45	39.49%	This is due to significant increase in current assets during the current year
2	Debt-equity ratio (in times)	Total Debt	Shareholder's Equity	0.75	0.66	13.31%	There is no significant change (i.e. change more than 25% as compared to the immediately previous financial year) in the key financial ratios.
3	Debt service coverage ratio (in times)	Earnings available for debt service	Debt Service	4.10	2.50	64.18%	This is due to significant increase in profit margin during the current year
4	Return on equity ratio (in %)	Net Profits after taxes – Preference Dividend (if any)	Average Shareholder's Equity	0.31	0.30	3.84%	There is no significant change (i.e. change more than 25% as compared to the immediately previous financial year) in the key financial ratios.
5	Inventory turnover ratio (in times)	Cost of goods sold OR sales	Average Inventory	7.30	5.10	43.27%	This is due to significant increase in sales during the current year compared to the immediately previous financial year
6	Trade receivables turnover ratio (in times)	Net Credit Sales	Average Accounts Receivable	5.25	5.77	-8.91%	There is no significant change (i.e. change more than 25% as compared to the immediately previous financial year) in the key financial ratios.
7	Trade payables turnover ratio (in times)	Net Credit Purchases	Average Trade Payables	9.93	12.02	-17.42%	There is no significant change (i.e. change more than 25% as compared to the immediately previous financial year) in the key financial ratios.
8	Net capital turnover ratio (in times)	Net Sales	Average Working Capital	4.80	6.31	-23.82%	There is no significant change (i.e. change more than 25% as compared to the immediately previous financial year) in the key financial ratios.
9	Net profit ratio (in %)	Net Profit	Net Sales	0.17	0.12	40.50%	This is due to significant increase in profit margin during the current year compared to the immediately previous financial year
10	Return on capital employed (in %)	Earning before interest and taxes	Capital Employed	0.29	0.29	-1.23%	There is no significant change (i.e. change more than 25% as compared to the immediately previous financial year) in the key financial ratios.
11	Return on investment (in %)	Income generated from invested funds	Average invested funds in treasury investments	-	-	-	Not Applicable

For Surender Kumar Singhal & Co.
Chartered Accountants
Firm Reg No.: 009156N

Sd/-
CA. Surender Singhal
Partner
M. No. 087072

Place: New Delhi
Date:

For and on behalf of the Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director
DIN:00077095

Sd/-
Archna Manocha
Director & CFO
DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

Sceptre Medical (India) Limited
(formerly known as "Sceptre Medical (India) Private Limited")

Note No. 32 Disclosure as per Accounting Standard - 18 on 'Related Party Disclosures'

Following are the related parties and transactions made with them during the year.

Key Management Personnel	Mr. Sanjay Manocha	Director
	Mr. Kartik Palta	Director
	Mr. Yogesh Sachdeva	Director
	Ms. Archna Manocha	Director
Relatives of Key Management Personnel (KMP)	Mr. Siddartha Manocha	Director's Son
	Mr. Aryan Manocha	Director's Son
Entities in which KMP/Relatives of KMP can exercise significant influence	M S Medicals Private Limited	Subsidiary Company (w.e.f. 01.04.2025)
	Sceptre Medical Devices Private Limited	Subsidiary Company (w.e.f. 30.03.2026), earlier Associate Company
	Ayka Medical Inc	Director relative is proprietor
	Manocha Surgicals	Director relative is proprietor
	Organics Wipes LLP	Director relative is designated partner in LLP
	Organic Wipes and Cosmetics	Director relative is partner in firm

Detail of related party transactions during the year ended ₹ (In Lakhs)

Particulars	31.03.2026	31.03.2025
Salary		
Mr Sanjay Manocha	45.00	39.00
Mr. Kartik Palta	38.93	9.30
Mr. Yogesh Sachdeva	35.79	7.50
Ms. Archna Manocha	27.00	27.00
Mr. Siddartha Manocha	11.89	9.75
Mr. Aryan Manocha	12.75	-
Loan Received		
Sanjay Manocha	119.50	125.90
Kartik Palta	44.84	83.65
Yogesh Sachdeva	241.15	103.83
Repayment of Loan		
Sanjay Manocha	166.47	78.93
Kartik Palta	79.84	48.65
Yogesh Sachdeva	311.15	33.83
Loan Given		
M S Medicals Private Limited	559.70	-
Interest received		
M S Medicals Private Limited	12.14	-
Purchase of Goods		
M S Medicals Private Limited	47.03	-
Sceptre Medical Devices Private Limited	-	0.53
Ayka Medical Inc	4.78	2.30
Organics Wipes LLP	67.29	-
Sale of Goods		
M S Medicals Private Limited	1900.61	861.23
Sceptre Medical Devices Private Limited	3.38	0.50
Ayka Medical Inc	0.13	-
Manocha Surgicals	2.41	4.42
Organics Wipes LLP	92.27	-
Organic wipes and Cosmetics	0.40	-

Balances outstanding as at ₹ (In Lakhs)

Particulars	31.03.2026	31.03.2025
Debtors/ (Creditors)		
M S Medicals Private Limited	308.12	(2.06)
Sceptre Medical Devices Private Limited	-	-
Ayka Medical Inc	(0.43)	(0.04)
Organics Wipes LLP	(0.22)	-
Organic wipes and Cosmetics	18.47	-
Short term loans and advances		
M S Medicals Private Limited	570.63	-
Balance outstanding of Loans		
Sanjay Manocha	-	(46.97)
Kartik Palta	-	(35.00)
Yogesh Sachdeva	-	(70.00)

Note No: 33 **Earnings and expenditure in foreign currency** **₹ (In Lakhs)**

Particulars	31.03.2026	31.03.2025
1. CIF Value of Imports	38.82	-
2. Expenditure in Foreign Currency	-	-
(a) Outward Remittance	48.21	-
(b) Travel Expenditure	-	4.22
3. Consumption of imported Raw Material components and spare parts	12.51	-
4. Earning in foreign Currency --	9.13	-

Note No: 34 **Additional Regulatory Information**

(i) Details of crypto currency or virtual currency

The Company has neither traded nor invested in Crypto currency or Virtual Currency for the year ended 31.03.2026. Further, the Company has also not received any deposits or advances from any person for the purpose of trading or investing in Crypto Currency or Virtual Currency.

(ii) Compliance with approved scheme of arrangements

The company has not entered into any scheme of such arrangements.

(iii) Undisclosed income

During the Periods, the Company has not surrendered or disclosed as income any transactions not recorded in the books of accounts in the course of tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961)

(iv)Relationship with struck off companies

The Company does not have any transactions with the companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956 for the year ended March 31, 2026 and March 31, 2025.

(v) Compliance with numbers of layers of companies

The Company is in compliance with the number of layers of companies in accordance with clause 87 of Section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017 For the year ended March 31, 2026 and March 31, 2025.

(vi) Utilisation of borrowed funds and share premium

During the year ended March 31, 2026 and March 31, 2025, the Company has not advanced or Loans or invested funds (either borrowed funds or share premium or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall:
i. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
ii. provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.
During the year ended March 31, 2026 and March 31, 2025, the Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
i. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
ii. provide any guarantee, security, or the like on behalf of the ultimate beneficiaries.

(vii) No Wilful Defaulter

The Company has not been declared Wilful Defaulter by any bank or financial institution or government or any government

(viii) Details of Benami Property held

The Company do not have any Benami property, where any proceeding has been initiated or pending against the company for holding any Benami Property.

(ix) Registration of charges or satisfaction with Registrar of Companies (ROC)

The Company do not have any charge or satisfaction which is yet to be registered with ROC beyond the statutory period.

(x) Loans or Advances in the nature of loans are granted to promoters, directors, KMPs and the related parties

The Company does not have any loans and advances in the nature of loans to promoters, directors, KMP and other related parties.

Note No: 35 **Security of current assets against borrowings from banks or financial institutions on the basis of security of current assets:**

Quarter	Name of bank	Particulars of Securities Provided	Amount as per books of account	Amount as reported in the quarterly return/ statement	Differences in percentage	Reason for material discrepancies
Jun/2025	Punjab National Bank	Current assets and movable fixed assets (except vehicle)	NA	NA	NA	No material discrepancies
Sep/2025	Punjab National Bank	Current assets and movable fixed assets (except vehicle)	NA	NA	NA	No material discrepancies
Dec/2025	Punjab National Bank	Current assets and movable fixed assets (except vehicle)	2008.52	2007.08	0.07%	No material discrepancies
Mar/2026	Punjab National Bank	Current assets and movable fixed assets (except vehicle)	1892.63	1892.62	0.00%	No material discrepancies

For Surender Kumar Singhal & Co.
Chartered Accountants
Firm Reg No.: 009156N

Sd/-
CA. Surender Singhal
Partner
M.No. 087072

Place: New Delhi
Date:

For and on behalf of Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director
DIN:00077095

Sd/-
Archna Manocha
Director & CFO
DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

INDEPENDENT AUDITORS' REPORT

TO THE MEMBERS OF SCEPTRE MEDICAL (INDIA) LIMITED

Report on the Audit of Consolidated Financial Statements

Opinion

We have audited the Consolidated Financial Statements of **Sceptre Medical (India) Limited** *(hereinafter referred to as the "Holding Company")* and its subsidiaries *(Holding Company and its subsidiaries together referred to as "the Group")* which comprises the Consolidated Balance Sheet as at March 31, 2026, the Consolidated Statement of Profit and Loss and the Consolidated Statement of Cash Flows for the year then ended and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information *(hereinafter referred to as "the consolidated financial statements").*

In our opinion and to the best of our information and according to the explanations given to us, and based on our audit of the financial statements of the Holding Company and its subsidiaries, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting standards prescribed under section 133 of the Act read with the Companies (Accounting Standards), Rules 2021 and other accounting principles generally accepted in India, of the Consolidated State of Affairs of the Group as at March 31, 2026, its Consolidated Profit and Consolidated Cash Flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the consolidated financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in terms of the Code of Ethics issued by the Institute of Chartered Accountants of India and the relevant provisions of the Act and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

We draw attention to Note 2.3 to the consolidated financial statements, which describes the principles of consolidation and the basis of accounting for the subsidiaries included in the consolidated financial statements. As stated in the said note, during the financial year 2025-26, Sceptre Medical (India) Limited acquired 100% shareholding in MS Medicals Private Limited with effect from 1 April 2025, and accordingly, the financial statements of the said entity have been fully consolidated on a line-by-line basis by combining its assets, liabilities, income and expenses with those of the holding Company after elimination of intra-group transactions and balances.

The said note further explains that Sceptre Medical (India) Limited held 40% shareholding in Sceptre Medical Devices Private Limited, which was accounted for as an associate up to 29 March 2026. Upon obtaining control through the right to appoint the majority of the Board of Directors, Sceptre Medical Devices Private Limited became a subsidiary of the Holding Company with effect from 30 March 2026. Accordingly, Sceptre Medical Devices Private Limited has been accounted for as an associate up to 29 March 2026 and consolidated as a subsidiary from 30 March 2026 onwards. The financial impact of the aforesaid accounting treatment has been disclosed in the said note.

Our opinion is not modified in respect of this matter.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined that there are no key audit matters to communicate in our report.

Information other than the Consolidated Financial Statements and Auditors' Report thereon

The Holding Company's management and board of directors are responsible for the preparation and presentation of the other information. The other information comprises the information included in the Annual Report, including its Annexures, but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Responsibility of Management for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance, and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act.

The respective Board of Directors of the companies included in the Group are responsible for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the respective companies and for preventing and detecting frauds and other irregularities; selection, application and maintenance of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error which have been used for the purpose of preparation of the consolidated financial statements by the Holding Company.

In preparing the consolidated financial statements, the respective management and Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective companies included in the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective management either intends to liquidate the respective company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the respective companies.

Auditor's Responsibility for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of the consolidated financial statements and remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure A statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143(3) of the Act, we report that:

    a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

    b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books.

    c) The Consolidated Balance Sheet, Consolidated Statement of Profit and Loss and Consolidated Statement of Cash Flows dealt with by this Report are in agreement with the books of account.

    d) In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act.

    e) On the basis of the written representations received from the directors as on 31st March, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

    f) With respect to the adequacy of the internal financial controls with reference to the consolidated financial statements of the Holding Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

    g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Group does not have any pending litigations which would impact its financial position, except as disclosed in note no. 37 of the consolidated financial statements.

ii. The Group did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company or its subsidiary companies.

iv. a) The respective managements of the Holding Company and its subsidiary companies have represented that, to the best of their knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Holding Company or its subsidiary companies to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company or its subsidiary companies ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

b) The respective managements of the Holding Company and its subsidiary companies have represented that, to the best of their knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the Holding Company or its subsidiary companies from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Holding Company or its subsidiary companies shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

c) Based on such audit procedures that we have considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause iv(a) and iv(b) contain any material misstatement.

v. The Holding Company and its subsidiaries has not declared or paid dividend during the year.

vi. Based on our examination which included test checks, the Holding Company and its subsidiary companies, in respect of financial year commencing on 1st April 2025, have used an accounting software for maintaining their books of account which has a feature of recording audit trail (edit log) facility and the same has been operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with and the audit trail has been preserved by the Holding Company and its subsidiary companies as per the statutory requirements for record retention.

For SURENDER KUMAR SINGHAL & CO.
Chartered Accountants
FRN 009156N

Sd/-
CA Surender Singhal
Partner
M. N. 087072
Place: New Delhi
Date: 06.06.2026

UDIN: 26087072NJGLRD4313

Annexure A to the Auditors' Report

[Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' of our Report of even date to the members of **SCEPTRE MEDICAL (INDIA) LIMITED** on the accounts of the company for the year ended **31st March, 2026**]

On the basis of such checks as we considered appropriate and according to the information and Explanations given to us during the course of our audit, we report that:

(xxi) In our opinion and according to the information and explanations given to us, the following qualifications or adverse remarks reported by the respective auditors in the Companies (Auditor's Report) Order, 2020 reports of the companies included in the consolidated financial statements are as under:

Sr. No	Name of the entities	CIN	Holding Company/ Subsidiary/ JV/ Associate	Clause number of the CARO report which is unfavourable or qualified or adverse
1	Sceptre Medical (India) Limited	U33112DL2010PLC204626	Parent Company	-
2	MS Medicals Private Limited	U85110DL2008PTC175791	Subsidiary Company	Clause (vii)(b)
3	Sceptre Medical Devices Private Limited	U33100DL2002PTC113888	Subsidiary Company	-

For SURENDER KUMAR SINGHAL & CO.
Chartered Accountants
FRN 009156N

Sd/-
CA Surender Singhal
Partner
M. N. 087072
Place: New Delhi
Date: 06.06.2026

UDIN: 26087072NJGLRD4313

Annexure B to the Auditors' Report

ANNEXURE TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF SCEPTRE MEDICAL (INDIA) LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")
(Referred to in paragraph 2(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to consolidated financial statements of **SCEPTRE MEDICAL (INDIA) LIMITED** (hereinafter referred to as "the Holding Company") and its subsidiary companies, as of 31 March 2026, in conjunction with our audit of the consolidated financial statements of the Holding Company for the year then ended.

In our opinion, and based on the consideration of the reports of the Holding Company and its subsidiary companies on the internal financial controls with reference to financial statements/financial information of the subsidiary companies, the Holding Company and such subsidiary companies have, in all material respects, adequate internal financial controls with reference to consolidated financial statements and such internal financial controls were operating effectively as at 31 March 2026, based on "the internal financial controls with reference to financial statements criteria established by such companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India."

Management's Responsibility for Internal Financial Controls

The respective company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the respective company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the

Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors of the relevant subsidiary, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to consolidated financial statements of the Holding Company.

Meaning of Internal Financial Controls with Reference to Consolidated Financial Statements

A company's internal financial control with reference to consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to consolidated financial statements includes those policies and procedures that

(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and

(3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the consolidated financial statements.

Inherent Limitations of Internal Financial Controls with reference to Consolidated Financial Statements

Because of the inherent limitations of internal financial controls with reference to consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to consolidated financial statements to future periods are subject to the risk that such controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For SURENDER KUMAR SINGHAL & CO.
Chartered Accountants
FRN 009156N

Sd/-

CA Surender Singhal
Partner
M. N. 087072
Place: New Delhi
Date: 06.06.2026

UDIN: 26087072NJGLRD4313

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Consolidated Balance Sheet

₹ (In Lakhs)

	Particulars	Note No.	As at 31.03.2026	As at 31.03.2025
I	**EQUITY AND LIABILITIES**			
1	**Shareholders' Funds**			
	(a) Share Capital	3	134.71	117.19
	(b) Reserves and Surplus	4	2856.15	1192.83
	(c) Minority Interest	5	204.49	-
2	**Non-current liabilities**			
	(a) Long-Term Borrowings	6	1397.78	487.41
	(b) Deferred Tax Liabilities (net)	7	41.46	31.61
	(c) Long-Term Provisions	8	87.42	18.26
3	**Current liabilities**			
	(a) Short-Term Borrowings	9	1891.99	379.31
	(b) Trade Payables	10		
	(A) Total outstanding dues of micro enterprises and small enterprises; and		278.86	169.61
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises		213.87	62.90
	(c) Other Current Liabilities	11	494.55	171.80
	(d) Short Term Provisions	12	266.30	109.60
	TOTAL		**7867.58**	**2740.53**
II.	**ASSETS**			
1	**Non Current Assets**			
	(a) Property, Plant and Equipment and Intangible assets			
	(i) Property, Plant and Equipment	13	1843.41	1288.75
	(ii) Intangible assets		0.12	0.21
	(iii) Capital Work-in-progress	14	474.55	-
	(b) Goodwill	15	37.56	-
	(c) Non-Current Investments	16	-	86.88
	(d) Other Non-Current Assets	17	226.80	68.31
2	**Current Assets**			
	(a) Inventories	18	1249.36	711.97
	(b) Trade Receivables	19	3021.15	523.92
	(c) Cash and Cash Equivalents	20	501.50	24.18
	(d) Short Term Loans and Advances	21	451.22	21.54
	(e) Other Current Assets	22	61.91	14.77
	TOTAL		**7867.58**	**2740.53**

The accompanying notes form an integral part of financial statements

As per our report of even date attached

For Surender Kumar Singhal & Co.
Chartered Accountants
Firm Reg No.: 009156N

Sd/-
CA. Surender Singhal
Partner
M.No. 087072

Place: New Delhi
Date:

For and on behalf of Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director
DIN:00077095

Sd/-
Archna Manocha
Director & CFO
DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Consolidated Statement of Profit & Loss

₹ (In Lakhs)

	Particulars	Note No.	For the year ended 31.03.2026	For the year ended 31.03.2025
	Income:			
I	Revenue from operations	23	6794.51	2869.45
II	Other Income	24	50.70	6.09
III	**Total Income (I+II)**		**6845.21**	**2875.54**
	Expenses:			
	Cost of materials consumed	25	2452.52	1347.97
	Purchases of Stock-in-Trade	26	1385.84	408.42
	Changes in Inventories of finished goods and Stock-in-Trade	27	18.44	(98.91)
	Employee Benefits Expense	28	768.07	365.43
	Finance Costs	29	141.29	64.77
	Depreciation and Amortization Expense	30	107.52	70.07
	Other Expenses	31	515.87	236.96
IV	**Total expenses**		**5389.57**	**2394.72**
V	**Profit before exceptional and extraordinary items and tax (III - IV)**		1455.64	480.82
VI	Share of Profit of Associate accounted for using Equity Method		38.71	4.94
VII	**Profit before tax (V+VI)**		1494.35	485.76
VIII	**Tax expense:**			
	(1) Current Tax		351.99	125.00
	(2) Deferred Tax		(10.96)	(35.28)
IX	**Profit (Loss) for the period (V-VI)**		1153.32	396.04
X	Share of Profit attributable to Parent Company		1129.90	396.04
	Share of Profit attributable to minority interest		23.42	-
XI	**Earning per equity share:**	32		
	(a) Basic (in Rs.)		91.19	33.79
	(b) Diluted (in Rs.)		91.19	33.79

The accompanying notes form an integral part of financial statements

As per our report of even date

For Surender Kumar Singhal & Co.
Chartered Accountants
Firm Reg No.: 009156N

Sd/-
CA. Surender Singhal
Partner
M. No. 087072
Place: New Delhi
Date:

For and on behalf of the Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director
DIN:00077095

Sd/-
Archna Manocha
Director & CFO
DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

Sceptre Medical (India) Limited
(formerly known as "Sceptre Medical (India) Private Limited")
Consolidated Cash Flow Statement

₹ (In Lakhs)

Particulars	For the year ended 31.03.2026	For the year ended 31.03.2025
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit Before Tax	1494.35	485.76
Less: Share of profit in associate	38.71	4.94
Profit before exceptional and extraordinary items and tax	**1455.64**	**480.82**
Adjustment For:		
(A) Depreciation And Amortization Expense	107.52	70.07
(B) Finance Charges	141.29	64.77
(C) Provision For Gratuity And Leave Encashment	27.18	18.71
(E) Profit on sale of fixed Assets	(11.34)	(0.04)
(F) Interest on FDR	(9.38)	(2.29)
(G) Loss on sale of investments	-	14.16
(H) Foreign Exchange fluctuation	1.90	0.05
Operating Profit Before Working Capital Changes	**1712.82**	**646.25**
Adjustment For:		
(A) (Increase)/Decrease In Inventories	97.61	(298.32)
(B) (Increase)/Decrease In Trade Receivables	(1767.19)	(52.48)
(C) (Increase)/Decrease In Loans & Advances	(167.90)	17.01
(D) (Increase)/Decrease In Other Assets	(23.60)	(8.45)
(E) Increase /(Decrease) In Trade Payables	71.13	139.62
(F) Increase /(Decrease) in Other Liabilities & Provisions	178.40	49.38
Cash generated from operations	101.26	493.01
Less: Direct Taxes Paid (Net Of Refund)	294.16	76.66
Net Cash generated from Operating Activities (A)	**(192.89)**	**416.35**
B. CASH FLOW FROM INVESTING ACTIVITIES		
(A) Purchase of property plant & equipment including capital work-in-progress	(735.35)	(563.56)
(B) Sale of Fixed Assets	33.00	0.10
(C) Loss on Sale of Investment	-	(14.16)
(D) Investment in subsidiary	(432.83)	-
(E) (Increase)/ Decrease In Other investments	-	215.23
(F) (Increase)/ Decrease In Non-Current Assets	(98.38)	(52.63)
(G) Interest And Other Income	9.38	2.29
Net Cash generated from Investing Activities (B)	**(1224.18)**	**(412.73)**
C. Cash Flow From Financing Activities		
(A) Proceeds/(Repayment) of Long-Term Borrowings	577.91	(146.49)
(B) Proceeds/(Repayment) of Short-Term Borrowings	842.24	184.05
(C) Interest Paid	(141.29)	(64.77)
(D) Issue of new Equity Shares including Securities Premium	598.64	-
Net Cash generated from Financing Activities (C)	**1877.50**	**(27.21)**
Net Increase In Cash & Cash Equivalents (A)+(B)+(C)	460.42	(23.59)
Opening Balance – Cash & Cash Equivalents	24.18	47.76
Add: Cash acquired on acquisition of control of Sceptre Medical Devices Private Limited	16.90	-
Closing Balance - Cash & Cash Equivalents	**501.50**	**24.18**

For Surender Kumar Singhal & Co.
Chartered Accountants
Firm Reg No.: 009156N

Sd/-
CA. Surender Singhal
Partner
M. No. 087072
Place: New Delhi
Date:

For and on behalf of the Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director
DIN:00077095

Sd/-
Archna Manocha
Director & CFO
DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

1 **Corporate Information**

Sceptre Medical (India) Limited ("the Company") was originally incorporated on 24th June, 2010 under the provisions of the Companies Act, 1956 as a Private Limited Company. Subsequently, the Company was converted into a Public Limited Company pursuant to the applicable provisions of the Companies Act, 2013, and its name was changed to Sceptre Medical (India) Limited with effect from 21st January, 2026.

The Company is engaged in the business of manufacturing, trading and distribution of medical devices, infection control products, disinfectants and hygiene solutions, including wet wipes for healthcare, institutional and personal care applications. The Company operates manufacturing facilities in Haryana and caters to hospitals, healthcare institutions, dialysis centres and retail customers through its distribution network across India

The Company has two subsidiaries, namely Sceptre Medical Devices Private Limited and M S Medical Private Limited, engaged in the healthcare and medical consumables segments.

2 **Significant Accounting Policies**

2.1 **Basis of Preparation of Consolidated Financial Statements**

The consolidated financial statements of the Company have been prepared in accordance with the generally accepted accounting principles in India ("Indian GAAP") and comply, in all material respects, with the Accounting Standards notified under Section 133 of the Companies Act, 2013 and the Companies (Accounting Standards) Rules, 2021.The financial statements have been prepared on an accrual basis and under the historical cost convention. The accounting policies have been applied consistently.

2.2 **Current / Non-Current Classification:**

Any asset or liability is classified as current if it satisfies any of the following conditions:

i. the asset/liability is expected to be realised/settled in the Company's normal operating cycle;
ii. the asset is intended for sale or consumption;
iii. the asset/liability is held primarily for the purpose of trading;
iv the asset/liability is expected to be realised/ settled within twelve months after the reporting period;
v the asset is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date;
vi in the case of a liability, the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

All other assets and liabilities are classified as non-current.

Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current – non- current classification of assets and liabilities.

2.3 **Principles of Consolidation**

The consolidated financial statements relate to **Sceptre Medical (India) Limited** (the Company) and its erstwhile subsidiary companies **MS Medicals Private Limited** and **Sceptre Medical Devices Private Limited.**

Following subsidiary has been considered in the preparation of the consolidated financial statements:

Name of the Company	Relationship	% of Holding	
		March 31, 2026	March 31, 2025
MS Medicals Private Limited	Subsidiary	100.00%	0.00%
Sceptre Medical Devices Private Limited	Subsidiary	40.00%	40.00%

MS Medicals Private Limited (Wholly Owned Subsidiary)

During the financial year 2025-26, Sceptre Medical (India) Limited acquired the 100% shareholding of MS Medical Private Limited on 1st April, 2025.

The financial statements of the M S Medicals Private Limited have been fully consolidated by combining its assets, liabilities, income, and expenses with those of the parent company. Intra-group transactions, balances, income, and expenses have been eliminated in full to ensure that only external transactions are reflected. The share of profit or loss of the M S Medicals Private Limited has been entirely included in the consolidated financial statements. The financial statements of the M S Medicals Private Limited have been prepared up to the same reporting date to ensure consistency in consolidation.

Sceptre Medical Devices Private Limited (Board-Controlled Subsidiary)

Sceptre Medical (India) Limited held a 40% shareholding in Sceptre Medical Devices Private Limited, and accordingly, the said company was classified as an associate company. Further, with effect from 30th March 2026, it became a subsidiary company pursuant to the acquisition of control by the holding company through the right to appoint and control the majority of the Board of Directors.

The financial statements of Sceptre Medical Devices Private Limited have been accounted for using the equity method for the period from 1st April 2025 to 29th March 2026. Subsequently, from 30th March 2026 to 31st March 2026, the financial statements of Sceptre Medical Devices Private Limited have been consolidated with those of the parent company on a line-by-line basis by combining its assets, liabilities, income, and expenses with those of the parent company.

2.4	**Use of Estimates and Judgements** In preparation of the financial statements, the Company is required to make judgments, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and the associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and the underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods affected significant judgments and estimates about the carrying amount of assets and liabilities include useful lives of tangible and intangible assets, impairment of Tangible assets, Intangible assets including goodwill, investments, employee benefits and other provisions and recoverability of deferred tax assets.
2.5	**Functional and presentation currency** These Financial Information are presented in Indian Rupees (₹), which is also its functional currency. All amounts have been rounded off to two decimal places to the nearest lakhs, unless otherwise indicated. Amount less then ₹ 1,000 have been presented as "0.00"
2.6	**Property, Plant and Equipment and Intangible Assets** Property, Plant and Equipment are stated at cost less accumulated depreciation and impairment losses, if any. Cost comprises of all expenses incurred to bring the assets to its present location and condition. Borrowing cost directly attributable to the acquisition /construction are included in the cost of fixed assets. Adjustments arising from exchange rate variations attributable to the fixed assets are capitalized. The company has adopted cost model for all class of items of Property, Plant and Equipment. In case of new projects / expansion of existing projects, expenditure incurred during construction / preoperative period including interest and finance charge on specific / general purpose loans, prior to commencement of commercial production are capitalized. The same are allocated to the respective on completion of construction / erection of the capital project / fixed assets. Subsequent expenditures related to an item of tangible asset are added to its book value only if they increase the future economic benefits from the existing asset beyond its previously assessed standard of performance. Depreciation on Fixed Assets is provided on Straight Line Method (SLM)/ Written Down Value Method (WDV) as applicable, over the estimated useful life of the Assets in the manner prescribed in Schedule II of the Act. Depreciation on additions to assets or on sale / discernment of assets, is calculated pro-rata basis from the month of such addition or up to the month of such sale/discardment, as the case may be. Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized on a Straight Line Method (SLM) basis over their estimated useful lives from the date they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors, including the effects of obsolescence, demand, competition, and other economic factors (such as the stability of the industry, and known technological advances), and the level of maintenance expenditures required to obtain the expected future cash flows from the asset. Amortization methods and useful lives are reviewed periodically including at each financial year end.
2.7	**Borrowing Cost** Borrowing costs include interest, other costs incurred in connection with borrowing and exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to the interest cost. General and specific borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognized in Statement of Profit and Loss in the period in which they are incurred.
2.8	**Impairment of Assets** The Management periodically assesses using external and internal sources, whether there is an indication that an asset may be impaired. An impairment loss is recognized wherever the carrying value of an asset exceeds its recoverable amount. The recoverable amount is higher of the asset's net selling price and value in use, which means the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. An impairment loss for an asset is reversed only when the reversal can be related objectively to an event occurring after the impairment loss was recognized. The carrying amount of an asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation had no impairment loss been recognized for the asset in prior years). As per Accounting Standard (AS-28) impairment of assets the company has carried the Impairment test during the year. There is no material impairment loss in the carried cost in the assets in the books and the recoverable amount is not lower than the carrying amount in the accounts.
2.9	**Inventories** As per (AS) 2, the inventories are physically verified at regular intervals by the management. Inventories comprising raw materials, finished goods and stock-in-trade are valued at the lower of cost and net realisable value. Cost of raw materials and stock-in-trade includes purchase cost and related expenses and is determined on FIFO basis. Cost of finished goods includes raw materials, direct labour and applicable overheads.

2.10 Foreign Currency Transactions

Conversion

Foreign currency monetary items are reported using the closing rate.

Non-monetary items, which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction.

Exchange Differences

Exchange differences arising on the settlement or reporting of monetary items at rates different from those at which they were initially recorded during the year, or reported in previous audited financial statement, are recognized as income or expense in the Statement of Profit and Loss.

2.11 Cash and Cash equivalents

Cash comprises cash on hand and demand deposits with banks, Cash equivalents are short term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

2.12 Depreciation and amortization

Depreciation on Fixed Assets is provided on Straight Line Method (SLM) / Written Down Value (WDV) as applicable, over the estimated useful life of the Assets in the manner prescribed in Schedule II of the Act.

Depreciation on additions to assets or on sale / discernment of assets, is calculated prorate basis from the month of such addition or up to the month of such sale/discardment, as the case may be.

2.13 Cash Flow Statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financial activities of the company are segregated based on the available information.

2.14 Revenue Recognition

Revenue from the operations is recognized on generally accepted accounting principal and when it is earned and no significant uncertainty exists as to its ultimate collection and includes taxes, wherever applicable.

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The capital gain on sale of investments if any are recognized on completion of transaction. No notional profit/loss are recognized on such investments. Interest income is recognized on time proportion basis, when it is accrued and due for payment.

2.15 Employee Benefits

i) Defined Contribution Plans: Contributions to the employees' regional Provident Fund, Employees Pension Scheme and Employees' State Insurance are recognized as defined contribution plan and charged as expenses during the period in which the employees perform the services. The Company has no obligation, other than the contribution payable to the respective funds.

ii) Defined Benefit Plans : Retirement benefits in the form of Gratuity and Leave Encashment are considered as defined benefit plan and determined on actuarial valuation using the Projected Unit Credit Method at the balance sheet date. Actuarial Gains or Losses through re-measurement of the net obligation of a defined benefit liability or asset is recognized in Profit and Loss account.

2.16 Current and deferred tax

Tax expense for the period, comprising current tax and deferred tax, are included in the determination of the net profit or loss for the period. Current tax is measured at the amount expected to be paid to the tax authorities in accordance with the taxation laws prevailing in the respective jurisdictions.

Deferred tax is recognised for all the timing differences, subject to the consideration of prudence in respect of deferred tax assets. Deferred tax assets are recognised and carried forward only to the extent that there is a reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. Deferred tax assets and liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted on the Balance Sheet date. In situations, where the Company has unabsorbed depreciation or carry forward losses under tax laws, all deferred tax assets are recognised only to the extent that there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits. At each Balance Sheet date, the Company re-assesses unrecognised deferred tax assets, if any.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle the asset and the liability on a net basis. Deferred tax assets and deferred tax liabilities are offset when there is a legally enforceable right to set off assets against liabilities representing current tax and where the deferred tax assets and the deferred tax liabilities relate to taxes on income levied by the same governing taxation laws

2.17 Provisions and Contingent Liabilities

Provisions: Provisions are recognised when there is a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance sheet date and are not discounted to its present value

Contingent Liabilities: Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non occurrence of one or more uncertain future events not wholly within the control of the company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

2.18 Earning Per Share

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Earnings considered in ascertaining the Company's earnings per share is the net profit for the period after deducting any attributable tax thereto for the period. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average numbers of shares outstanding during the period is adjusted for the effects of all new equity shares issued during the year.

2.19

The previous year figures have been regrouped / reclassified, wherever necessary to confirm to the current year presentation

2.20 Group Restructuring, Acquisition of Subsidiaries and Proforma Combined Financial Information
Background and Rationale

During the financial year ended 31 March 2026, the Company undertook a strategic group restructuring and business consolidation exercise. The restructuring was carried out with the objective of creating an integrated business platform, achieving operational synergies, strengthening management oversight, improving scalability, and aligning the Group structure in connection with the Company's proposed Initial Public Offering ("IPO") and long-term growth strategy.
Pursuant to the aforesaid restructuring, the Company presently holds the following subsidiaries:

S.No	Entity Consolidation	Shareholding	Nature of Subsidiary	Effective Date of Consolidation
1	M S Medicals Private Limited	100%	Wholly Owned Subsidiary	01.04.2025
2	Sceptre Medical Devices Private Limited	40%	Subsidiary (Control Acquired)	30.03.2026

a) Acquisition of Wholly Owned Subsidiary – M S Medicals Private Limited

The Company acquired 100% of the equity share capital of M S Medicals Private Limited ("Wholly Owned Subsidiary") with effect from 01 April 2025, pursuant to which the wholly owned subsidiary became a wholly owned subsidiary of the Company. Accordingly, the financial results of the wholly owned subsidiary have been consolidated in these Consolidated Financial Statements with effect from 01 April 2025, in accordance with Accounting Standard (AS) 21 – Consolidated Financial Statements.
Prior to the said acquisition, the wholly owned subsidiary was substantially held by the same promoter and shareholder group as the Company. The acquisition was undertaken as part of the Group's overall business consolidation and integration strategy and does not represent an arm's length transaction with an independent third party.

b) Acquisition of Control over Sceptre Medical Devices Private Limited ("Controlled Subsidiary")

The Company has held a 40% equity participation in Sceptre Medical Devices Private Limited ("Controlled Subsidiary") since July 2024. The remaining 60% equity shareholding has been, and continues to be, held by the promoters and shareholders of the Company in substantially the same proportion as their respective shareholding in the Company. Accordingly, no external or outside shareholder group has at any point held any economic interest in the Controlled Subsidiary.
Pursuant to the execution of an amended Shareholders' Agreement and consequential modifications to the Articles of Association of the Controlled Subsidiary, both effective from 30 March 2026, the Company acquired the right to control the composition of the Board of Directors and the relevant operational and financial decision-making processes of the Controlled Subsidiary. Accordingly, the Controlled Subsidiary has been consolidated in these Consolidated Financial Statements with effect from 30 March 2026, being the date on which such control was contractually and legally established, in accordance with AS 21.

c) Common Ownership and Commercial Substance

The restructuring and consolidation transactions described above were undertaken amongst entities that are substantially held, controlled, and economically aligned by the same promoter and shareholder group. The transactions were not carried out with any external or independent party and are intended to achieve operational integration, unified strategic direction, optimisation of resources, improved administrative efficiencies, and consolidation of business operations, thereby enhancing overall Group positioning and scale.

The management is of the view that the present Group structure appropriately reflects the commercial substance and the integrated operational framework of the businesses carried on by the respective entities.

d) Proforma Combined Financial Information

For informational and management assessment purposes only, the following table sets out the indicative proforma combined financial parameters of the Group, as if the present Group structure, governance rights, and control arrangements had been operational from 01 April 2025, i.e., from the beginning of the financial year ended 31 March 2026:

Particulars	Indicative Proforma Amount (In Lakhs)
Aggregate Revenue from Operations	10385.47
Less: Inter Company Sales	2673.90
Net Revenue from Operations	7711.56
Aggregate Operating Profit	1925.66
Less: Interest	206.80
Less: Depreciation	142.65
Aggregate Profit Before Tax	1576.20
Less: Taxes	364.81
Aggregate Profit After Tax	1211.39

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Notes on Consolidated Financial Statements

Note No. 3: Share Capital **₹ (In Lakhs)**

Particulars	As at 31.03.2026	As at 31.03.2025
Authorized Share Capital :		
2,50,00,000 Equity shares of Rs.10/- each	2500.00	200.00
(Previous Year 20,00,000 Equity Shares)		
Issued, Subscribed and Paid up :		
13,47,062 Equity Shares of Rs.10/- each fully paid up	134.71	117.19
(Previous Year 11,71,944 Equity Shares of Rs.10/- each)		
Total	**134.71**	**117.19**

The Reconciliation of the numbers of shares outstanding is set out below:

Authorised Share Capital **₹ (In Lakhs)**

	31.03.2026		31.03.2025	
Particulars	**No. of Shares**	**Amount**	**No. of Shares**	**Amount**
Opening Share Capital	2,000,000	200.00	20.00	200.00
Add: Increased during the year	23,000,000	2300.00	-	-
Closing Share Capital	25,000,000	2500.00	2,000,000	200.00

Issued, Subscribed and Paid up

	31.03.2026		31.03.2025	
Particulars	**No. of Shares**	**Amount**	**No. of Shares**	**Amount**
Opening Share Capital	1,171,944	117.19	1,171,944	117.19
Add: Shares issued During the year	175,118	17.51	-	-
Closing Share Capital	1,347,062	134.71	1,171,944	117.19

Details of Shareholders holding more than 5% Shares:

	31.03.2026		31.03.2025	
Particulars	**No. of Shares**	**% held**	**No. of Shares**	**% held**
Name of the Shareholders				
Sanjay Manocha	292,986	21.75	292,986	25.00
Archna Manocha	135,167	10.03	135,167	11.53
Kartik Palta	169,931	12.61	169,931	14.50
Yogesh Sachdeva	234,389	17.40	234,389	20.00
Sukesh Arora	140,633	10.44	140,633	12.00
Mona Sachdeva	93,756	6.96	93,756	8.00
Charu Palta	64,457	4.79	64,457	5.50

The details of Shareholding of Promoters:

	31.03.2026		31.03.2025	
Particulars	**No. of Shares**	**% held**	**No. of Shares**	**% held**
Name of the Shareholders				
Sanjay Manocha	292,986	21.75	292,986	25.00
Archna Manocha	135,167	10.03	135,167	11.53
Kartik Palta	169,931	12.61	169,931	14.50
Yogesh Sachdeva	234,389	17.40	234,389	20.00
Sukesh Arora	140,633	10.44	140,633	12.00
Mona Sachdeva	93,756	6.96	93,756	8.00
Charu Palta	64,457	4.79	64,457	5.50
Siddharth Manocha	40,625	3.02	40,625	3.47

Terms/rights attached to Equity Shares

The company has only one class of equity shares having a par value of Rs.10 per share. All these shares have same rights and preferences with respect to payment of dividend, repayment of capital and voting.

During the year, the company has issued 1,21,235 equity shares of ₹ 10 each at a premium of ₹ 154 per share, 53,883 equity shares of ₹ 10 each at a premium of ₹ 732 per share aggregating to ₹ 598.64 lakhs (including securities premium of ₹ 581.13 lakhs) for cash consideration.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

Note No. 4: Reserves And Surplus ₹ (In Lakhs)

Particulars	As at 31.03.2026	As at 31.03.2025
Securities Premium		
Opening Balance	82.50	82.50
Add: Shares issued during the year	581.13	-
Total (A)	**663.63**	**82.50**
Profit & Loss Account		
Opening Balance	1110.33	714.90
Add: Profit for the year	1129.90	396.04
Add: Prior Period Tax*	(47.71)	(0.61)
Total (B)	**2192.52**	**1110.33**
Grand Total (A+B)	**2856.15**	**1192.83**

*Prior period tax adjustments relating to earlier years have been adjusted directly against the balance of Reserves & Surplus during the year and accordingly have not been recognised in the current year's Statement of Profit & Loss.

Note No. 5: Minority Interest

Particulars	As at 31.03.2026	As at 31.03.2025*
Opening balance	-	-
Add: Pre-Holding subsidiary relationship retained earnings up to 29.03.2026 (Sceptre Medical Devices Private Limited)	181.07	-
Add: Share in profit post Holding subsidiary relationship (Sceptre Medical Devices Private Limited)	23.42	-
Total	**204.49**	**-**

*The Consolidated Financial Statements for the year ended 31 March 2025 do not include any minority interest, as the Group comprised only the Parent Company and its associate during the year. Accordingly, no minority interest was required to be recognised or presented separately in the Consolidated Financial Statements for the year ended 31st March 2025.

Sceptre Medical (India) Limited
(formerly known as "Sceptre Medical (India) Private Limited")
Notes on Consolidated Financial Statements

Particulars	As at 31.03.2026	As at 31.03.2025
		₹ (In Lakhs)
Note No. 6: Long Term Borrowings		
Secured		
From Banks		
(i) Term Loans	1608.91	714.75
(ii) Vehicle Loan	68.11	-
Unsecured		
(a) From banks:		
(i) Term Loan	48.37	-
	1725.39	714.75
Less: current maturities of long-term borrowings		
(i) Term Loans	310.73	227.34
(ii) Vehicle Loan	16.87	-
	327.61	227.34
Total	**1397.78**	**487.41**
Note No. 7: Deferred Tax Liabilities		
On account of difference between tax value and book value	41.46	31.61
Total	**41.46**	**31.61**
Note No. 8: Long Term Provisions		
Provision for Gratuity	67.08	16.68
Provision for Leave Encashment	20.34	1.59
Total	**87.42**	**18.26**
Note No. 9 : Short Term Borrowings		
Secured		
(A) from banks		
(i) Cash credit	1007.40	-
(ii) Current Maturities of Long Term Borrowings;		
- Term Loans	285.55	227.34
- Vehicle Loans	16.87	-
Unsecured		
(A) from banks		
(i) Working Capital Loan	199.96	-
(ii) Current maturities of long-term borrowings		
- Term Loans	25.19	-
(B) from related parties	341.29	151.97
(C) from others	15.73	-
Total	**1891.99**	**379.31**
Note No. 10: Trade Payables		
Due to Micro and Small enterprises	278.86	169.61
Due to Others	213.87	62.90
Total	**492.74**	**232.51**
Note No. 11: Other Current Liabilities		
Statutory Dues Payable	142.92	56.07
Salary Payable	67.42	34.30
Expenses Payable	54.69	29.36
Advance From Customers	149.52	52.07
Advance against property	80.00	-
Total	**494.55**	**171.80**
Note No. 12: Short Term Provisions		
Provision for Income Tax	263.10	109.15
Provision for Gratuity	1.69	0.35
Provision for Leave Encashment	1.51	0.10
Total	**266.30**	**109.60**

Sceptre Medical (India) Limited
(formerly known as "Sceptre Medical (India) Private Limited")
Terms & Conditions of Loans for Note No. 6 & 9

S.no	Company	Loan account Number	Lender	Nature of facility	Sanctioned Amount (₹ in Lakhs)	Outstanding as on March 31, 2026 (₹ in Lakhs)	Rate of Interest / Margin	Repayment Terms	Security/ Principal terms and conditions
1	Sceptre Medical (India) Limited	050210SZ00000014	PUNJAB NATIONAL BANK	Term Loan	92.70	59.58	8.65%	Repayable in 24 EMI of ₹ 370000*23, ₹389034*1	Mortgage Plot No. 230-31
2	Sceptre Medical (India) Limited	050210CN00000117	PUNJAB NATIONAL BANK	Term Loan	28.62	17.52	8.40%	Repayable in 15 EMI of ₹ 185000*14, Rs. 86,691*1	Mortgage Plot No. 230-31
3	Sceptre Medical (India) Limited	050210CN00000135	PUNJAB NATIONAL BANK	Term Loan	105.68	89.05	8.40%	Repayable in 37 EMI of ₹ 277000*36, ₹ 318323*1	Mortgage Plot No. 230-31
4	Sceptre Medical (India) Limited	050210CN00000126	PUNJAB NATIONAL BANK	Term Loan	162.00	142.49	8.40%	Repayable in 49 EMI of ₹ 325000*48, ₹ 274163*1	Mortgage Plot No. 230-31
5	Sceptre Medical (India) Limited	050210CN00000108	PUNJAB NATIONAL BANK	Term Loan	186.00	150.99	8.40%	Repayable in 28 EMI of ₹ 550000*1, ₹ 600000*12, ₹ 675000*12, ₹ 750000*2 , ₹ 698166*1	Mortgage Plot No. 230-31
6	Sceptre Medical (India) Limited	D000ELKE	SIDBI	Term Loan	1700.00	986.00	8%	Repayable in 84 EMI of ₹ 2361000*83, ₹ 2369000*1	Mortgage Khewat No. 100, Killa No.19/5 (Liwan)
7	Sceptre Medical (India) Limited	GST SAHAY	SIDBI	Bill Discounting	100.00	100.00	10%	-	Unsecured Loan
8	Sceptre Medical (India) Limited	D000380Z	SIDBI	Term Loan	370.00	-	10%	Repayable in 72 EMI of ₹ 250000*6, ₹ 300000*6, ₹ 350000*12, ₹ 450000*12 , ₹ 550000*12, ₹ 600000*12, ₹ 675000*12, ₹ 750000*2, ₹ 700000*1	Mortgage Plot No. 230-231
9	Sceptre Medical (India) Limited	D0003CPP	SIDBI	Term Loan	81.00	-	8%	Repayable in 36 EMI of ₹ 225000*36	Mortgage Plot No. 230-31
10	Sceptre Medical (India) Limited	D0003ZTA	SIDBI	Term Loan	100.00	-	8%	Repayable in 54 EMI of ₹ 185000*53, ₹ 195000*1	Mortgage Plot No. 230-31
11	Sceptre Medical (India) Limited	D000547D	SIDBI	Term Loan	200.00	-	8%	Repayable in 54 EMI of ₹ 370000*53, ₹ 390000*1	Mortgage Plot No. 230-31
12	Sceptre Medical (India) Limited	D000BGA6	SIDBI	Term Loan	175.00	-	9%	Repayable in 54 EMI of ₹ 325000*53, ₹ 275000*1	Mortgage Plot No. 230-31
13	Sceptre Medical (India) Limited	D00082XV	SIDBI	Term Loan	150.00	-	8%	Repayable in 54 EMI of ₹ 277000*53, ₹ 319000*1	Mortgage Plot No. 230-31
14	MS Medical Private Limited	CVR036111197737	AXIS BANK LTD	Auto Loan	8.26	3.59	10%	Repayable in 35 EMI of ₹ 27400*35	Hypothecate - TATA - EV
15	MS Medical Private Limited	603170410000044 (07-01-2022)	Bank of India	Star GECL 1.0	15.54	-	8.00%	Repayable in 36 EMI of ₹ 48339*36 (AFTER 24 MONTH EMI START) (Closed)	
16	MS Medical Private Limited	603160510000381	Bank of India	Auto Loan	8.00	-	9.00%	Repayable in 84 EMI of ₹ 12851*84 (CLOSED)	Hypothecate - MARUTI - DZIRE
17	MS Medical Private Limited	300014863630019 (07-10-2013)	Deutsche Bank Loan	Loan Against Property	37.00	-	10.00%	Repayable in 144 EMI of ₹ 44407*144 (CLOSED)	30-B 1ST FLOOR POCKET -C ASHOK VIHAR -P-3, DELHI -110052
18	MS Medical Private Limited	141545213 (15-02-2023)	HDFC BANK LTD	Business Loan	50.00	3.39	15.00%	Repayable in 36 EMI of ₹ 172715*36	
19	MS Medical Private Limited	149703690 (22-02-2024)	HDFC BANK LTD	Auto Loan	30.00	19.59	9.00%	Repayable in 60 EMI of ₹ 62348*60	Hypothecate - Galaxy - Toyota
20	MS Medical Private Limited	050210CN00000098 (17-07-2025)	PUNJAB NATIONAL BANK	Machine Loan	67.50	57.31	9.00%	Repayable in 60 EMI of ₹162500*60	Hypothecate - DIALYSIS MACHINE
21	MS Medical Private Limited	603130110000034	Bank of India	Cash Credit Limit	325.00	284.50	11.00%	Monthly interest Approx. - 255000	MORTGAGE PLOT NO. N-1 , Stock and Debtors , 1 crore FDR
22	Sceptre Medical Devices Private Limited	D0007OAM	SIDBI	Term Loan	150.00	86.75	8.20%	Repayable in 54 EMI of ₹ 275000*53, ₹ 425000*1,	Mortgage Plot No. 187
23	Sceptre Medical Devices Private Limited	D0005ZQG	SIDBI	Term Loan	100.00	42.65	8.30%	Repayable in 54 EMI of ₹ 185000*53, ₹ 195000*1	Mortgage Plot No. 187
24	Sceptre Medical Devices Private Limited	D0003ZT6	SIDBI	Term Loan	38.00	10.70	8.35%	Repayable in 36 EMI of ₹ 105000*35, ₹ 125000*1	Mortgage Plot No. 187
25	Sceptre Medical Devices Private Limited	D000145H	SIDBI	Cash Credit	250.00	246.62	8.96%	-	Secured by hypothecation of stock, sundry debtors, factory building and personal guarantee of directors.
26	Sceptre Medical Devices Private Limited	350014958450028	Deutsche Bank	Business Loan	32.50	21.62	14.15%	Repayable in 54 EMI of ₹ 277000*53, ₹ 319000*1	Unsecured
27	Sceptre Medical Devices Private Limited	BLN000302001175	Yes Bank	Business Loan	40.00	23.36	15.25%	Repayable in 36 EMI of ₹ 139152*35, ₹ 139127*1	Unsecured
28	Sceptre Medical Devices Private Limited	23109048	Kotak Mahindra Bank	Auto Loan	16.99	10.81	9.25%	Repayable in 60 EMI of ₹ 35475*60	Hypothecate - Tata Nexon Car
29	Sceptre Medical Devices Private Limited	GST-SAHAY	SIDBI	Bill Discounting	100.00	99.96	9.50%	-	Unsecured
30	Sceptre Medical Devices Private Limited	D0003660	SIDBI	Term Loan	50.00	-	5.00%	Repayable in 54 EMI of ₹ 92500*53, ₹ 97500*1	Mortgage Plot No. 187
31	Sceptre Medical Devices Private Limited	D0003B33	SIDBI	Term Loan	33.62	-	8.65%	Repayable in 36 EMI of ₹ 94000*35, ₹ 72000*1	Mortgage Plot No. 187
32	Sceptre Medical Devices Private Limited	112605192	HDFC Bank	Auto Loan	20.13	-	8.05%	Repayable in 60 EMI of ₹ 40869*60	Hypothecate - T-Rock Car

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Note 10.1 **Trade payables ageing schedule for the year:**

Outstanding for following periods from due date of payment (2025-26)

₹ (In Lakhs)

S. No	Particulars	Not due	Unbilled amount	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
	MSME	-	-	278.68	0.18	-	-	278.86
	Others	-	-	201.79	12.08	-	-	213.87
	Disputed dues-MSME	-	-	-	-	-	-	-
	Disputed dues-Others	-	-	-	-	-	-	-
	Total	**-**	**-**	**480.47**	**12.26**	**-**	**-**	**492.74**

Outstanding for following periods from due date of payment (2024-25)

₹ (In Lakhs)

S. No	Particulars	Not due	Unbilled amount	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
	MSME	-	-	168.03	1.58	-	-	169.61
	Others	-	-	62.90	-	-	-	62.90
	Disputed dues-MSME	-	-	-	-	-	-	-
	Disputed dues-Others	-	-	-	-	-	-	-
	Total	**-**	**-**	**230.93**	**1.58**	**-**	**-**	**232.51**

For and on behalf of the Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director
DIN:00077095

Sd/-
Archna Manocha
Director & CFO
DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Note No. 13 Property, Plant and Equipment and Intangible assets

Financial Year 2025-26

₹ (In Lakhs)

Particulars	Original Cost				Depreciation				Net Book Value	
	As at 01.04.2025*	Additions	Deletion	As at 31.03.2026	As at 01.04.2025*	Depreciation for the Year	Adjusted	Total 31.03.2026	As at 31.03.2026	As at 31.03.2025*
PROPERTY, PLANT AND EQUIPMENT:										
Land	679.99	18.04	4.72	693.31	-	-	-	-	693.31	679.99
Factory Building	383.51	-	-	383.51	91.94	7.79	-	99.73	283.78	291.57
Plant & Machinery	845.72	204.14	49.61	1000.25	305.31	45.73	32.93	318.11	682.14	540.41
Office Equipment	99.04	8.10	-	107.14	65.77	12.70	-	78.46	28.68	33.27
Furniture & Fixture	73.76	3.08	-	76.85	28.50	6.05	-	34.55	42.30	45.27
Computer	34.82	17.54	-	52.36	27.94	6.77	-	34.71	17.65	6.88
Vehicles	250.19	9.90	10.17	249.92	135.91	28.36	9.91	154.37	95.56	114.28
Total Property, Plant & Equipment (A)	**2367.03**	**260.81**	**64.49**	**2563.34**	**655.36**	**107.41**	**42.83**	**719.93**	**1843.41**	**1711.67**
INTANGIBLE ASSETS										
Softwares	2.44	-	-	2.44	2.20	0.11	-	2.32	0.12	0.23
Total Intangible Assets (B)	**2.44**	**-**	**-**	**2.44**	**2.20**	**0.11**	**-**	**2.32**	**0.12**	**0.23**
Grand Total (A+B)	**2369.47**	**260.81**	**64.49**	**2565.78**	**657.56**	**107.52**	**42.83**	**722.25**	**1843.53**	**1711.91**

*Values related to Property, Plant and Equipment and Intangible assets with respect to Sceptre Medical Devices Private Limited have been considered for the period 30th March 2026 to 31st March 2026 i.e. the period during which it was considered a subsidiary of Sceptre Medical (India) Limited.

Sceptre Medical (India) Limited
(formerly known as "Sceptre Medical (India) Private Limited")
Notes on Consolidated Financial Statements

₹ (In Lakhs)

Particulars	As at 31.03.2026	As at 31.03.2025
Note No. 14: Capital Work-in-Progress		
Building under construction	474.55	-
(Factory at Liwan, Sonipat, Haryana)		
Total	**474.55**	**-**
Note No. 15: Goodwill on acquisition of following subsidiaries		
MS Medical Private Limited	32.68	-
Sceptre Medical Devices Limited	4.88	-
Total	**37.56**	**-**
Note No. 16: Non Current Investments		
Investment in Associate		
Investment in equity instrument-unquoted		
Investment measured at Cost		
372000 (31 March 2025: 372000) Fully paid equity shares of Sceptre Medical Devices Private Limited of Rs. 10 each	-	86.88
Cost of acquisition - Rs. 81.94 Lakhs		
Profit Share till 31.03.2025 - Rs. 4.94 Lakhs		
Total	**-**	**86.88**
Note No. 17: Other Non Current Assets		
Security Deposits	45.42	33.81
FDR with Banks	181.38	34.50
Total	**226.80**	**68.31**
Note No. 18: Inventories		
Raw Material	879.04	558.50
Stock-in-Trade	230.86	6.93
Finished Goods	139.47	146.54
Total	**1249.36**	**711.97**
Note No. 19: Trade Receivables		
Secured, Considered good	**-**	**-**
Unsecured, considered good	3021.15	523.92
Doubtful	1.93	-
Less: Provision for Doubtful Debt	(1.93)	-
Total	**3021.15**	**523.92**
Note No. 20: Cash And Cash Equivalents		
Balance with Banks		
-In Current Accounts	466.43	20.32
-In Escrow Account	0.24	-
-FDR with Banks	24.71	-
Cash on Hand	10.12	3.86
Total	**501.50**	**24.18**
Note No. 21: Short Term Loans & Advances		
Advance against Capital Goods	180.62	-
Advance Against Purchase	270.27	3.83
Staff Advance	0.33	17.71
Total	**451.22**	**21.54**
Note No. 22: Other Current Assets		
VAT Refundable	-	1.05
GST Cash Ledger	0.10	0.12
GST Input Credit	13.60	2.44
GST Input Reco	9.34	8.83
GST Refund Receivable	29.77	-
IT Refund Receivable	-	1.34
Subsidy Receivable	1.57	-
Prepaid Expenses	7.54	0.98
Total	**61.91**	**14.77**

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Note 14.1 Capital Work-in-Progress ageing schedule for the year (2025-26): **₹ (In Lakhs)**

S. No.	Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
1	Building under construction	474.55	-	-	-	474.55
						-
	Total	**474.55**	**-**	**-**	**-**	**474.55**

Capital Work-in-Progress ageing schedule for the year (2024-25): **₹ (In Lakhs)**

S. No.	Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
1	Building under construction	-	-	-	-	-
						-
	Total	**-**	**-**	**-**	**-**	**-**

For and on behalf of the Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director
DIN:00077095

Sd/-
Archna Manocha
Director & CFO
DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Note 19.1 Trade Receivables ageing schedule for the year:

Outstanding for following periods from due date of payment (2025-26)

₹ (In Lakhs)

S. No	Particulars	Not due	Unbilled amount	Less than 6 Months	6 Months to 1 Year	1-2 years	2-3 years	More than 3 years	Total
	Undisputed Trade Receivables – considered good	-	-	2072.90	615.16	321.66	11.34	0.10	3021.15
	Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
	Disputed Trade Receivables – considered good	-	-	-	-	-	-	-	-
	Disputed Trade Receivables – considered doubtful	-	-	-	-	-	-	1.93	1.93
	Total	**-**	**-**	**2072.90**	**615.16**	**321.66**	**11.34**	**2.03**	**3023.08**

Outstanding for following periods from due date of payment (2024-25)

₹ (In Lakhs)

S. No	Particulars	Not due	Unbilled amount	Less than 6 Months	6 Months to 1 Year	1-2 years	2-3 years	More than 3 years	Total
	Undisputed Trade Receivables – considered good	-	-	509.84	1.16	2.46	-	10.47	523.92
	Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
	Disputed Trade Receivables – considered good	-	-	-	-	-	-	-	-
	Disputed Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
	Total	**-**	**-**	**509.84**	**1.16**	**2.46**	**-**	**10.47**	**523.92**

For and on behalf of the Board

Sd/- **Sanjay Manocha** Managing Director DIN:00076997	Sd/- **Kartik Palta** Whole Time Director DIN:01543913
Sd/- **Yogesh Sachdeva** Whole Time Director DIN:00077095	Sd/- **Archna Manocha** Director & CFO DIN:02020796
Sd/- **Vidushi** Company Secretar M. No. A71077	**-** -

Sceptre Medical (India) Limited
(formerly known as "Sceptre Medical (India) Private Limited")
Notes on Consolidated Financial Statements

₹ (In Lakhs)

Particulars	For the year ended 31.03.2026	For the year ended 31.03.2025
Note No. 23: Revenue From Operations		
Sale of Products	6715.69	2869.45
Sale of services	78.82	-
Total	**6794.51**	**2869.45**
Note: 23.1		
(i) Sale of products comprises following:		
Domestic sales	6619.07	2833.78
Export sales	96.61	35.67
(ii) Sale of Services		
Domestic sales	78.82	-
Total	**6794.51**	**2869.45**
Note No. 24: Other Income		
Interest on FDR	9.38	2.29
Reimbursement-Govt. Schemes	-	3.75
Interest on Income Tax Refund	0.21	-
GST Refund	29.77	-
Profit on Sale of Fixed Assets	11.34	0.04
Total	**50.70**	**6.09**
Note No. 25: Cost Of Materials Consumed		
Add: Inventories at the beginning of the Year	958.21	359.10
Add: Purchase during the year	2373.35	1547.38
	3331.56	1906.48
Less: Inventories at the end of the Year	879.04	558.50
Total	**2452.52**	**1347.97**
Note No. 26: Purchase Of stock-in-trade		
Purchases of goods	1385.84	408.42
Total	**1385.84**	**408.42**
Note No. 27: Changes In inventories of finished goods and stock-in-trade		
Stock-in-trade		
Inventories at the end of the Year	274.58	6.93
Inventories at the beginning of the Year	242.22	27.81
Change in stock-in-trade (A)	**(32.36)**	**20.88**
Finished Goods		
Inventories at the end of the Year	95.74	146.54
Inventories at the beginning of the Year	146.54	26.75
Change in finished goods (B)	**50.80**	**119.79**
Total (C=A+B)	**18.44**	**(98.91)**
Note No. 28: Employee Benefits Expense		
Directors' remuneration	146.73	82.80
Salary, Wages & Incentives	561.17	244.45
Contribution to Provident and other funds	20.93	16.54
Provision for Gratuity	20.05	17.02
Provision for Leave Encashment	10.95	1.69
Staff Welfare Expenses	8.25	2.93
Total	**768.07**	**365.43**

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Notes on Consolidated Financial Statements

₹ (In Lakhs)

Particulars	For the year ended 31.03.2026	For the year ended 31.03.2025
Note No. 29: Finance Costs		
Bank Charges	27.13	0.89
Bank Interest	114.16	63.88
Total	**141.29**	**64.77**
Note No. 30: Depreciation And Amortization Expenses		
On Tangible & Intangible Assets	107.52	70.07
Total	**107.52**	**70.07**
Note No. 31: Other Expenses		
Audit Fee	6.50	1.25
Custom Duty	2.02	0.62
Clearing & Forwarding Charges	1.36	0.58
Foreign Exchange Fluctuation	1.90	0.05
Power & Fuel	39.44	25.55
Repair & Maintenance Expenses	24.66	15.81
Rent	39.96	20.82
Freight & Courier Charges	95.63	26.82
Job Work Charges	4.96	-
Conveyance & Travelling Expenses	81.33	33.46
Communication Expense	2.87	1.23
Office Expenses	11.38	4.98
Printing & Stationery Expenses	12.51	4.06
Provision for Doubtful Debts	0.80	-
GST Expenses	2.62	5.16
Insurance Expenses	4.05	4.43
Fees & Taxes	4.07	2.65
Loss on sale of Investment	-	14.16
Professional Fee	49.10	25.69
Testing fee	7.61	3.72
Business Promotion Expenses	54.85	13.60
Discount Allowed	18.47	21.15
Commission	28.48	0.07
Security Charges	4.76	5.18
Festival Expenses	9.44	1.44
Website Expenses	3.32	4.26
Miscellaneous Expenses	3.75	0.21
Total	**515.87**	**236.96**
Note No. 31.1: Payment made to auditors (inclusive of taxes)		
For Statutory Audit	5.55	1.18
For Taxation Matters	2.12	0.30
	7.67	1.48

Note No. 32: Earning Per Equity Share

Particulars	For the year ended 31.03.2026	For the year ended 31.03.2025
1.Net Profit after tax as per Statement of Profit and Loss attributable to Equity Shareholders (₹ in Lakhs)	1153.32	396.04
2. Weighted Average number of equity shares used as denominator for calculating EPS	1,264,725	1,171,944
3. Weighted Average number of equity shares used as denominator for calculating EPS	1,264,725	1,171,944
4. Basic Earnings per Share (On Face value of ₹ 10/ per share)	91.19	33.79
5. Diluted Earnings per Share (On Face value of ₹ 10/ per share)	91.19	33.79

Sceptre Medical (India) Limited

(formerly known as "Sceptre Medical (India) Private Limited")

Note No. 33: 'Disclosure Regarding analytical ratios:

	Ratio	Numerator	Denominator	Current Period	Previous Period	% Variance	Reason for variance
1	Current Ratio (in times)	Current Assets	Current Liabilities	1.68	1.45	15.77%	There is no significant change (i.e. change more than 25% as compared to the immediately previous financial year) in the key financial ratios.
2	Debt-equity ratio (in times)	Total Debt	Shareholder's Equity	1.03	0.66	55.61%	This is due to increase in total debt being high than increase in equity .
3	Debt service coverage ratio (in times)	Earnings available for debt service	Debt Service	5.02	2.39	110.12%	This is due to significant increase in profit margin during the current year
4	Return on equity ratio (in %)	Net Profits after taxes – Preference Dividend (if any)	Average Shareholder's Equity	0.36	0.30	19.39%	There is no significant change (i.e. change more than 25% as compared to the immediately previous financial year) in the key financial ratios.
5	Inventory turnover ratio (in times)	Cost of goods sold OR sales	Average Inventory	6.93	5.10	35.89%	This is due to significant increase in sales during the current year compared to the immediately previous financial year
6	Trade receivables turnover ratio (in times)	Net Credit Sales	Average Accounts Receivable	3.83	5.77	-33.52%	This is due to receivables growing comparatively faster than sales.
7	Trade payables turnover ratio (in times)	Net Credit Purchases	Average Trade Payables	10.37	12.02	-13.77%	There is no significant change (i.e. change more than 25% as compared to the immediately previous financial year) in the key financial ratios.
8	Net capital turnover ratio (in times)	Net Sales	Average Working Capital	5.34	6.31	-15.24%	There is no significant change (i.e. change more than 25% as compared to the immediately previous financial year) in the key financial ratios.
9	Net profit ratio (in %)	Net Profit	Net Sales	0.17	0.14	22.98%	There is no significant change (i.e. change more than 25% as compared to the immediately previous financial year) in the key financial ratios.
10	Return on capital employed (in %)	Earning before interest and taxes	Capital Employed	0.34	0.15	127.25%	This is due to significant increase in profit margin during the current year compared to the immediately previous financial year
11	Return on investment (in %)	Income generated from invested funds	Average invested funds in treasury investments	NA	NA	NA	No investments are held by the company

For Surender Kumar Singhal & Co.
Chartered Accountants
Firm Reg No.: 009156N

Sd/-
CA. Surender Singhal
Partner
M. No. 087072

Place: New Delhi
Date:

For and on behalf of the Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director
DIN:00077095

Sd/-
Archna Manocha
Director & CFO
DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

Sceptre Medical (India) Limited
(formerly known as "Sceptre Medical (India) Private Limited")

Note No. 34 Disclosure as per Accounting Standard - 18 on 'Related Party Disclosures'

Following are the related parties and transactions made with them during the year.

Key Management Personnel	Archna Manocha	Director
	Kartik Palta	Director
	Sanjay Manocha	Director
	Yogesh Sachdeva	Director
Relatives of Key Management Personnel (KMP)	Aryan Manocha	Director's Son
	Mahi Arora	Director's Daughter
	Manya Sachdeva	Director's Daughter
	Mona Sachdeva	Director's Wife
	Monica Arora	Director's Wife
	Rishika Arora	Director's Daughter
	Sattvik Palta	Director's Son
	Siddartha Manocha	Director's Son
	Sukesh Arora	Director in Subsidiary Company
Entities in which KMP/Relatives of KMP can exercise significant influence	Ayka Medical Inc	Director relative is proprietor
	M S Medicals Private Limited	Subsidiary Company (w.e.f. 01.04.2025)
	Manocha Surgicals	Director's relative is proprietor
	Organic wipes and Cosmetics	Director's relative is partner in firm
	Organics Wipes LLP	Director's relative is designated partner in LLP
	Sceptre Medical Devices Private Limited	Subsidiary Company (w.e.f. 30.03.2026), earlier Associate Company

Detail of related party transactions for the year ended **₹ (In Lakhs)**

Particulars	31.03.2026	31.03.2025
Remuneration/Salary		
Archna Manocha	27.00	27.00
Aryan Manocha	13.75	-
Kartik Palta	38.93	9.30
Mahi Arora	4.80	-
Manya Sachdeva	12.00	-
Mona Sachdeva	15.60	-
Monica Arora	9.60	-
Rishika Arora	0.48	-
Sanjay Manocha	45.00	39.00
Sattvik Palta	5.40	-
Siddartha Manocha	11.89	9.75
Sukesh Arora	-	-
Yogesh Sachdeva	35.79	7.50
Loans Received		
Archna Manocha	53.00	-
Kartik Palta	112.64	83.65
Sanjay Manocha	475.88	125.90
Sukesh Arora	274.78	-
Yogesh Sachdeva	521.65	103.83
Repayment of Loan		
Archna Manocha	53.25	-
Kartik Palta	119.84	48.65
Sanjay Manocha	341.47	78.93
Sukesh Arora	170.01	-
Yogesh Sachdeva	575.15	33.83
Purchases of Goods		
Ayka Medical Inc	6.66	2.30
Manocha Surgicals	21.07	-
Organic Wipes LLP	118.52	129.85
Sales of Goods		
Ayka Medical Inc	0.19	-
Manocha Surgicals	24.44	4.42
Organic wipes and Cosmetics	0.40	-
Organic Wipes LLP	92.27	215.10

Balance outstanding at the end of the year

Particulars	31.03.2026	31.03.2025
Debtors/(Creditors)		
Organic Wipes LLP	(0.22)	49.38
Ayka Medical Inc	(1.21)	(0.04)
Organic wipes and Cosmetics	18.47	-
Balances outstanding of Loans		
Kartik Palta	(18.65)	(35.00)
Sanjay Manocha	(135.15)	(46.97)

Sukesh Arora	(104.77)	-
Yogesh Sachdeva	(0.50)	-
Archna Manocha	-	-
Kartik Palta	(46.07)	-
Yogesh Sachdeva	(36.16)	(70.00)

Note No. 35 **Earnings and expenditure in foreign currency** **₹ (In Lakhs)**

Particulars	31.03.2026	31.03.2025
1. CIF Value of Imports	39.23	5.12
2. Expenditure in Foreign Currency		
(a) Outward Remittance	48.83	4.69
(b) Travel Expenditure	-	4.22
3. Consumption of imported Raw Material components and spare parts	17.77	-
4. Earning in foreign Currency	26.62	58.94

Note No. 36 **Additional Regulatory Information**

(i) Details of crypto currency or virtual currency

The Company has neither traded nor invested in Crypto currency or Virtual Currency for the year ended 31.03.2026. Further, the Company has also not received any deposits or advances from any person for the purpose of trading or investing in Crypto Currency or Virtual Currency.

(ii) Compliance with approved scheme of arrangements

The Company has not entered into any scheme of such arrangements.

(iii) Undisclosed income

During the Periods, the Company has not surrendered or disclosed as income any transactions not recorded in the books of accounts in the course of tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961)

(iv)Relationship with struck off companies

The Company does not have any transactions with the companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956 for the year ended March 31, 2026 and March 31, 2025.

(v) Compliance with numbers of layers of companies

The Company is in compliance with the number of layers of companies in accordance with clause 87 of Section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017 For the year ended March 31, 2026 and March 31, 2025.

(vi) Utilisation of borrowed funds and share premium

During the year ended March 31, 2026 and March 31, 2025, the Company has not advanced or Loans or invested funds (either borrowed funds or share premium or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall:
i. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
ii. provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.
During the year ended March 31, 2026 and March 31, 2025, the Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
i. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
ii. provide any guarantee, security, or the like on behalf of the ultimate beneficiaries.

(vii) No Wilful Defaulter

The Company has not been declared Wilful Defaulter by any bank or financial institution or government or any government authority.

(viii) Details of Benami Property held

The company does not have any benami property which is yet to be registered with ROC beyond the statutory period

(ix) Registration of charges or satisfaction with Registrar of Companies (ROC)

The Company has the following charges which are required to be registered with the Registrar of Companies:

Company Name	Name of Charge	Description of the charges or satisfaction	Statutory Date	the location of the Registrar	Period (in days or months) by which such charge had to be registered
MS Medicals Private Limited	HDFC Bank Limited	Vehicle Loan	21.03.2024	ROC, Delhi	30 Days
Sceptre Medical Devices Private Limited	HDFC Bank Limited	Vehicle Loan	07.10.2020	ROC, Delhi	30 Days
Sceptre Medical Devices Private Limited	Kotak Mahindra Prime Ltd	Vehicle Loan	28.02.2024	ROC, Delhi	30 Days

(x) Loans or Advances in the nature of loans are granted to promoters, directors, KMPs and the related parties

The Company does not have any loans and advances in the nature of loans to promoters, directors, KMP and other related parties.

Note No: 37 **Contingent Liabilities**

Statute	Financial Year	Demand Raised	Remarks
Income Tax Act, 1961 (TDS)	2025-26	Rs. 17,210	The aforesaid demand pertains to MS Medicals Private Limited and has arisen on account of a short payment of TDS. The matter is currently pending for rectification.

Note No: 38 **Security of current assets against borrowings from banks or financial institutions on the basis of security of current assets:**

Quarter	Name of bank	Particulars of Securities Provided	Amount as per books of account*	Amount as reported in the quarterly return/ statement	Differences in percentage	Reason for material discrepancies
Jun/2025	Bank of India, Punjab National Bank, Small Industries Development Bank of India	Current assets and movable fixed assets (except vehicle)	1254.29	1250.74	0.28%	No material discrepancies
Sep/2025	Bank of India, Punjab National Bank, Small Industries Development Bank of India	Current assets and movable fixed assets (except vehicle)	1410.25	1409.15	0.08%	No material discrepancies
Dec/2025	Bank of India, Punjab National Bank, Small Industries Development Bank of India	Current assets and movable fixed assets (except vehicle)	3731.59	3723.23	0.22%	No material discrepancies
Mar/2026	Bank of India, Punjab National Bank, Small Industries Development Bank of India	Current assets and movable fixed assets (except vehicle)	4578.63	4583.72	-0.11%	No material discrepancies

* The amounts stated above have been derived from the standalone balance sheets of the respective group companies and are presented prior to the elimination of inter-company balances.

For Surender Kumar Singhal & Co.
Chartered Accountants
Firm Reg No.: 009156N

Sd/-
CA. Surender Singhal
Partner
M.No. 087072

Place: New Delhi
Date:

For and on behalf of Board

Sd/-
Sanjay Manocha
Managing Director
DIN:00076997

Sd/-
Kartik Palta
Whole Time Director
DIN:01543913

Sd/-
Yogesh Sachdeva
Whole Time Director
DIN:00077095

Sd/-
Archna Manocha
Director & CFO
DIN:02020796

Sd/-
Vidushi
Company Secretary
M. No. A71077

SCEPTRE MEDICAL (INDIA) LIMITED

(Formerly known as Sceptre Medical (India) Private Limited)

CIN: U33112DL2010PLC204626

Registered Office: Lower Ground Floor, N-1, Satyawati Colony, Ashok Vihar, Phase- III, North West Delhi, Delhi, India, 110052

Tel: 011 4155 8987; Website: www.sceptremedical.com

Form MGT-11
Proxy Form

[Pursuant to section 105(6) of Companies Act, 2013 and rule 19(3) of The Companies (Management and Administration) Rules, 2014]

Name of the Member (s) ______________________________

Registered Address ______________________________

____

E-mail Id ______________________ Foilo No.______________________

I/We, being the member (s) holding____________ shares of the above-named company, hereby appoint

1. Name: ______________Address ______________

   E-mail Id: ______________Signature ______________, or failing him / her

2. Name: ______________Address ______________

   E-mail Id: ______________Signature ______________, or failing him / her

3. Name: ______________Address ______________

   E-mail Id: ______________Signature ______________, or failing him / her

4. Name: ______________Address ______________

   E-mail Id: ______________Signature ______________, or failing him / her

As my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 16th Annual General Meeting of the Company, to be held on Sunday, 27th day of September, 2026 a 12:00 PM at N-1, Lower Ground Floor, Satyawati Colony, Ashok Vihar, Phase-III, Delhi-110052, and at any adjournment thereof in respect of such resolutions as are indicated below:

	Resolutions	Optional*	
Ordinary Business		For	Against
1	Adoption of Audited Standalone and Consolidated Financial Statements for the year ended on March 31, 2026, together with the Report of Board of Directors and Auditors' thereon.		
2	Re-appointment of Mrs. Archna Manocha as a Director, who retires by rotation.		

3	Re-appoint Surender Kumar Singhal & Co., Chartered Accountants as statutory auditors of the Company and to fix their remuneration		

Signed this ____________ day of _________________2026.

Affix Revenue Stamp

_____________________ _______________________

Signature of shareholder Signature of Proxy holder (s)

Notes:

1. A Proxy need not be a member of the Company. Pursuant to the provisions of Section 105 of the Companies Act, 2013, a person can act as Proxy on behalf of not more than fifty members and holding in aggregate not more than 10% of the total share capital of the Company. Members holding more than 10% of the total share capital of the company may appoint a single person as proxy, who shall not act as proxy for any other member.
2. It is optional to put a 'X' in the appropriate column against the resolutions indicated in the Box. If you leave the 'For' or 'Against' column blank against any or all resolutions, your proxy will be entitled to vote in the manner as he/she thinks appropriate.
3. For the Resolutions and Notes, please refer to the Notice of the 16th Annual General Meeting of the Company.
4. This form of Proxy, to be effective, should be duly completed and deposited at the Registered Office of the Company at N-1, Lower Ground Floor, Satyawati Colony, Ashok Vihar, Phase-III, Delhi-110052, not later than 48 hours before the commencement of aforesaid meeting.

SCEPTRE MEDICAL (INDIA) LIMITED

(Formerly known as Sceptre Medical (India) Private Limited)

CIN: U33112DL2010PLC204626

Registered Office: Lower Ground Floor, N-1, Satyawati Colony, Ashok Vihar, Phase- III, North West Delhi, Delhi, India, 110052

Tel: 011 4155 8987; Website: www.sceptremedical.com

ATTENDANCE SLIP
To be surrendered at the time of entry

Folio No.______________

No. of Shares held_____________

I/We hereby record my/our presence at the 16th Annual General Meeting of the Company held on Sunday, the 27th day of September 2026, at 12.00 P.M held at the Registered Office of the Company at N-1, Lower Ground Floor, Satyawati Colony, Ashok Vihar, Phase-III, Delhi-110052.

________________________________ ________________________

Name of the Member / Proxy (In Block Letters) Signature of the Member / Proxy

Notes:

1. Members/Proxy Holders are requested to sign the Attendance Slip (specimen signature registered with the Company) and hand it over at the entrance of the Meeting venue.
2. No additional or duplicate Attendance Slip will be issued at the Meeting venue.
3. The Annual Report, including the Notice of the Annual General Meeting, is being circulated to the Members electronically. Members are requested to refer to the electronic copy of the Annual Report for the proceedings of the Meeting. Physical copies of the Annual Report will not be provided at the venue of the Annual General Meeting.
4. Members are requested to reach the venue of the Annual General Meeting well in time to facilitate smooth registration and attendance.
5. Please note that no gifts or gift coupons will be distributed at the venue of the Annual General Meeting.

ROUTE MAP TO THE REGISTERED OFFICE OF SCEPTRE MEDICAL (INDIA) LIMITED



Note: The map is indicative only and is not drawn to scale.